

# African Journal of Biotechnology

Volume 14 Number 28, 15 July, 2015

ISSN 1684-5315



*Academic  
Journals*

## ABOUT AJB

The **African Journal of Biotechnology (AJB)** (ISSN 1684-5315) is published weekly (one volume per year) by Academic Journals.

**African Journal of Biotechnology (AJB)**, a new broad-based journal, is an open access journal that was founded on two key tenets: To publish the most exciting research in all areas of applied biochemistry, industrial microbiology, molecular biology, genomics and proteomics, food and agricultural technologies, and metabolic engineering. Secondly, to provide the most rapid turn-around time possible for reviewing and publishing, and to disseminate the articles freely for teaching and reference purposes. All articles published in AJB are peer-reviewed.

## Submission of Manuscript

Please read the **Instructions for Authors** before submitting your manuscript. The manuscript files should be given the last name of the first author

[Click here to Submit manuscripts online](#)

If you have any difficulty using the online submission system, kindly submit via this email [ajb@academicjournals.org](mailto:ajb@academicjournals.org).

With questions or concerns, please contact the Editorial Office at [ajb@academicjournals.org](mailto:ajb@academicjournals.org).

## Editor-In-Chief

**George Nkem Ude, Ph.D**

*Plant Breeder & Molecular Biologist  
Department of Natural Sciences  
Crawford Building, Rm 003A  
Bowie State University  
14000 Jericho Park Road  
Bowie, MD 20715, USA*

## Editor

**N. John Tonukari, Ph.D**

*Department of Biochemistry  
Delta State University  
PMB 1  
Abraka, Nigeria*

## Associate Editors

**Prof. Dr. AE Aboulata**

*Plant Path. Res. Inst., ARC, POBox 12619, Giza, Egypt  
30 D, El-Karama St., Alf Maskan, P.O. Box 1567,  
Ain Shams, Cairo,  
Egypt*

**Dr. S.K Das**

*Department of Applied Chemistry  
and Biotechnology, University of Fukui,  
Japan*

**Prof. Okoh, A. I.**

*Applied and Environmental Microbiology Research  
Group (AEMREG),  
Department of Biochemistry and Microbiology,  
University of Fort Hare.  
P/Bag X1314 Alice 5700,  
South Africa*

**Dr. Ismail TURKOGLU**

*Department of Biology Education,  
Education Faculty, Firat University,  
Elaziğ,  
Turkey*

**Prof T. K. Raja, PhD FRSC (UK)**

*Department of Biotechnology  
PSG COLLEGE OF TECHNOLOGY (Autonomous)  
(Affiliated to Anna University)  
Coimbatore-641004, Tamilnadu,  
INDIA.*

**Dr. George Edward Mamati**

*Horticulture Department,  
Jomo Kenyatta University of Agriculture  
and Technology,  
P. O. Box 62000-00200,  
Nairobi, Kenya.*

**Dr. Gitonga**

*Kenya Agricultural Research Institute,  
National Horticultural Research Center,  
P.O Box 220,  
Thika, Kenya.*

## Editorial Board

**Prof. Sagadevan G. Mundree**

*Department of Molecular and Cell Biology  
University of Cape Town  
Private Bag Rondebosch 7701  
South Africa*

**Dr. Martin Fregene**

*Centro Internacional de Agricultura Tropical (CIAT)  
Km 17 Cali-Palmira Recta  
AA6713, Cali, Colombia*

**Prof. O. A. Ogunseitan**

*Laboratory for Molecular Ecology  
Department of Environmental Analysis and Design  
University of California,  
Irvine, CA 92697-7070. USA*

**Dr. Ibrahima Ndoye**

*UCAD, Faculte des Sciences et Techniques  
Departement de Biologie Vegetale  
BP 5005, Dakar, Senegal.  
Laboratoire Commun de Microbiologie  
IRD/ISRA/UCAD  
BP 1386, Dakar*

**Dr. Bamidele A. Iwalokun**

*Biochemistry Department  
Lagos State University  
P.M.B. 1087. Apapa – Lagos, Nigeria*

**Dr. Jacob Hodeba Mignouna**

*Associate Professor, Biotechnology  
Virginia State University  
Agricultural Research Station Box 9061  
Petersburg, VA 23806, USA*

**Dr. Bright Ogheneovo Agindotan**

*Plant, Soil and Entomological Sciences Dept  
University of Idaho, Moscow  
ID 83843, USA*

**Dr. A.P. Njukeng**

*Département de Biologie Végétale  
Faculté des Sciences  
B.P. 67 Dschang  
Université de Dschang  
Rep. du CAMEROUN*

**Dr. E. Olatunde Farombi**

*Drug Metabolism and Toxicology Unit  
Department of Biochemistry  
University of Ibadan, Ibadan, Nigeria*

**Dr. Stephen Bakiamoh**

*Michigan Biotechnology Institute International  
3900 Collins Road  
Lansing, MI 48909, USA*

**Dr. N. A. Amusa**

*Institute of Agricultural Research and Training  
Obafemi Awolowo University  
Moor Plantation, P.M.B 5029, Ibadan, Nigeria*

**Dr. Desouky Abd-El-Haleem**

*Environmental Biotechnology Department &  
Bioprocess Development Department,  
Genetic Engineering and Biotechnology Research  
Institute (GEBRI),  
Mubarak City for Scientific Research and Technology  
Applications,  
New Burg-Elarab City, Alexandria, Egypt.*

**Dr. Simeon Oloni Kotchoni**

*Department of Plant Molecular Biology  
Institute of Botany, Kirschallee 1,  
University of Bonn, D-53115 Germany.*

**Dr. Eriola Betiku**

*German Research Centre for Biotechnology,  
Biochemical Engineering Division,  
Mascheroder Weg 1, D-38124,  
Braunschweig, Germany*

**Dr. Daniel Masiga**

*International Centre of Insect Physiology and  
Ecology,  
Nairobi,  
Kenya*

**Dr. Essam A. Zaki**

*Genetic Engineering and Biotechnology Research  
Institute, GEBRI,  
Research Area,  
Borg El Arab, Post Code 21934, Alexandria  
Egypt*

**Dr. Alfred Dixon**

*International Institute of Tropical Agriculture (IITA)  
PMB 5320, Ibadan  
Oyo State, Nigeria*

**Dr. Sankale Shompole**

*Dept. of Microbiology, Molecular Biology and  
Biochemistry,  
University of Idaho, Moscow,  
ID 83844, USA.*

**Dr. Mathew M. Abang**

*Germplasm Program  
International Center for Agricultural Research in the  
Dry Areas  
(ICARDA)  
P.O. Box 5466, Aleppo, SYRIA.*

**Dr. Solomon Olawale Odemuyiwa**

*Pulmonary Research Group  
Department of Medicine  
550 Heritage Medical Research Centre  
University of Alberta  
Edmonton  
Canada T6G 2S2*

**Prof. Anna-Maria Botha-Oberholster**

*Plant Molecular Genetics  
Department of Genetics  
Forestry and Agricultural Biotechnology Institute  
Faculty of Agricultural and Natural Sciences  
University of Pretoria  
ZA-0002 Pretoria, South Africa*

**Dr. O. U. Ezeronye**

*Department of Biological Science  
Michael Okpara University of Agriculture  
Umudike, Abia State, Nigeria.*

**Dr. Joseph Hounhouigan**

*Maître de Conférence  
Sciences et technologies des aliments  
Faculté des Sciences Agronomiques  
Université d'Abomey-Calavi  
01 BP 526 Cotonou  
République du Bénin*

**Prof. Christine Rey**

*Dept. of Molecular and Cell Biology,  
University of the Witwatersand,  
Private Bag 3, WITS 2050, Johannesburg, South  
Africa*

**Dr. Kamel Ahmed Abd-Elsalam**

*Molecular Markers Lab. (MML)  
Plant Pathology Research Institute (PPathRI)  
Agricultural Research Center, 9-Gamma St., Orman,  
12619,  
Giza, Egypt*

**Dr. Jones Lemchi**

*International Institute of Tropical Agriculture (IITA)  
Onne, Nigeria*

**Prof. Greg Blatch**

*Head of Biochemistry & Senior Wellcome Trust  
Fellow  
Department of Biochemistry, Microbiology &  
Biotechnology  
Rhodes University  
Grahamstown 6140  
South Africa*

**Dr. Beatrice Kilel**

*P.O Box 1413  
Manassas, VA 20108  
USA*

**Dr. Jackie Hughes**

*Research-for-Development  
International Institute of Tropical Agriculture (IITA)  
Ibadan, Nigeria*

**Dr. Robert L. Brown**

*Southern Regional Research Center,  
U.S. Department of Agriculture,  
Agricultural Research Service,  
New Orleans, LA 70179.*

**Dr. Deborah Rayfield**

*Physiology and Anatomy  
Bowie State University  
Department of Natural Sciences  
Crawford Building, Room 003C  
Bowie MD 20715, USA*

**Dr. Marlene Shehata**

*University of Ottawa Heart Institute  
Genetics of Cardiovascular Diseases  
40 Ruskin Street  
K1Y-4W7, Ottawa, ON, CANADA*

**Dr. Hany Sayed Hafez**

*The American University in Cairo,  
Egypt*

**Dr. Clement O. Adebooye**

*Department of Plant Science  
Obafemi Awolowo University, Ile-Ife  
Nigeria*

**Dr. Ali Demir Sezer**

*Marmara Üniversitesi Eczacılık Fakültesi,  
Tıbbiye cad. No: 49, 34668, Haydarpaşa, İstanbul,  
Turkey*

**Dr. Ali Gazanchain**

*P.O. Box: 91735-1148, Mashhad,  
Iran.*

**Dr. Anant B. Patel**

*Centre for Cellular and Molecular Biology  
Uppal Road, Hyderabad 500007  
India*

**Prof. Arne Elofsson**

*Department of Biophysics and Biochemistry  
Bioinformatics at Stockholm University,  
Sweden*

**Prof. Bahram Goliaei**

*Departments of Biophysics and Bioinformatics  
Laboratory of Biophysics and Molecular Biology  
University of Tehran, Institute of Biochemistry  
and Biophysics  
Iran*

**Dr. Nora Babudri**

*Dipartimento di Biologia cellulare e ambientale  
Università di Perugia  
Via Pascoli  
Italy*

**Dr. S. Adesola Ajayi**

*Seed Science Laboratory  
Department of Plant Science  
Faculty of Agriculture  
Obafemi Awolowo University  
Ile-Ife 220005, Nigeria*

**Dr. Yee-Joo TAN**

*Department of Microbiology  
Yong Loo Lin School of Medicine,  
National University Health System (NUHS),  
National University of Singapore  
MD4, 5 Science Drive 2,  
Singapore 117597  
Singapore*

**Prof. Hidetaka Hori**

*Laboratories of Food and Life Science,  
Graduate School of Science and Technology,  
Niigata University.  
Niigata 950-2181,  
Japan*

**Prof. Thomas R. DeGregori**

*University of Houston,  
Texas 77204 5019,  
USA*

**Dr. Wolfgang Ernst Bernhard Jelkmann**

*Medical Faculty, University of Lübeck,  
Germany*

**Dr. Moktar Hamdi**

*Department of Biochemical Engineering,  
Laboratory of Ecology and Microbial Technology  
National Institute of Applied Sciences and  
Technology.  
BP: 676. 1080,  
Tunisia*

**Dr. Salvador Ventura**

*Department de Bioquímica i Biologia Molecular  
Institut de Biotecnologia i de Biomedicina  
Universitat Autònoma de Barcelona  
Bellaterra-08193  
Spain*

**Dr. Claudio A. Hetz**

*Faculty of Medicine, University of Chile  
Independencia 1027  
Santiago, Chile*

**Prof. Felix Dapare Dakora**

*Research Development and Technology Promotion  
Cape Peninsula University of Technology,  
Room 2.8 Admin. Bldg. Keizersgracht, P.O. 652,  
Cape Town 8000,  
South Africa*

**Dr. Geremew Bultosa**

*Department of Food Science and Post harvest  
Technology  
Haramaya University  
Personal Box 22, Haramaya University Campus  
Dire Dawa,  
Ethiopia*

**Dr. José Eduardo Garcia**

*Londrina State University  
Brazil*

**Prof. Nirbhay Kumar**

*Malaria Research Institute  
Department of Molecular Microbiology and  
Immunology  
Johns Hopkins Bloomberg School of Public Health  
E5144, 615 N. Wolfe Street  
Baltimore, MD 21205*

**Prof. M. A. Awal**

*Department of Anatomy and Histology,  
Bangladesh Agricultural University,  
Mymensingh-2202,  
Bangladesh*

**Prof. Christian Zwieb**

*Department of Molecular Biology  
University of Texas Health Science Center at Tyler  
11937 US Highway 271  
Tyler, Texas 75708-3154  
USA*

**Prof. Danilo López-Hernández**

*Instituto de Zoología Tropical, Facultad de  
Ciencias,  
Universidad Central de Venezuela.  
Institute of Research for the Development (IRD),  
Montpellier,  
France*

**Prof. Donald Arthur Cowan**

*Department of Biotechnology,  
University of the Western Cape Bellville 7535  
Cape Town,  
South Africa*

**Dr. Ekhaise Osaro Frederick**

*University Of Benin, Faculty of Life Science  
Department of Microbiology  
P. M. B. 1154, Benin City, Edo State,  
Nigeria.*

**Dr. Luísa Maria de Sousa Mesquita Pereira**

*IPATIMUP R. Dr. Roberto Frias, s/n 4200-465 Porto  
Portugal*

**Dr. Min Lin**

*Animal Diseases Research Institute  
Canadian Food Inspection Agency  
Ottawa, Ontario,  
Canada K2H 8P9*

**Prof. Nobuyoshi Shimizu**

*Department of Molecular Biology,  
Center for Genomic Medicine  
Keio University School of Medicine,  
35 Shinanomachi, Shinjuku-ku  
Tokyo 160-8582,  
Japan*

**Dr. Adewunmi Babatunde Idowu**

*Department of Biological Sciences  
University of Agriculture Abia  
Abia State,  
Nigeria*

**Dr. Yifan Dai**

*Associate Director of Research  
Revivacor Inc.  
100 Technology Drive, Suite 414  
Pittsburgh, PA 15219  
USA*

**Dr. Zhongming Zhao**

*Department of Psychiatry, PO Box 980126,  
Virginia Commonwealth University School of  
Medicine,  
Richmond, VA 23298-0126,  
USA*

**Prof. Giuseppe Novelli**

*Human Genetics,  
Department of Biopathology,  
Tor Vergata University, Rome,  
Italy*

**Dr. Moji Mohammadi**

*402-28 Upper Canada Drive  
Toronto, ON, M2P 1R9 (416) 512-7795  
Canada*

**Prof. Jean-Marc Sabatier**

*Directeur de Recherche Laboratoire ERT-62  
Ingénierie des Peptides à Visée Thérapeutique,  
Université de la Méditerranée-Ambrilia  
Biopharma inc.,  
Faculté de Médecine Nord, Bd Pierre Dramard,  
13916,  
Marseille cédex 20.  
France*

**Dr. Fabian Hoti**

*PneumoCarr Project  
Department of Vaccines  
National Public Health Institute  
Finland*

**Prof. Irina-Draga Caruntu**

*Department of Histology  
Gr. T. Popa University of Medicine and Pharmacy  
16, Universitatii Street, Iasi,  
Romania*

**Dr. Dieudonné Nwaga**

*Soil Microbiology Laboratory,  
Biotechnology Center. PO Box 812,  
Plant Biology Department,  
University of Yaoundé I, Yaoundé,  
Cameroon*

**Dr. Gerardo Armando Aguado-Santacruz**

*Biotechnology CINVESTAV-Unidad Irapuato  
Departamento Biotecnología  
Km 9.6 Libramiento norte Carretera Irapuato-  
León Irapuato,  
Guanajuato 36500  
Mexico*

**Dr. Abdolkaim H. Chehregani**

*Department of Biology  
Faculty of Science  
Bu-Ali Sina University  
Hamedan,  
Iran*

**Dr. Abir Adel Saad**

*Molecular oncology  
Department of Biotechnology  
Institute of graduate Studies and Research  
Alexandria University,  
Egypt*

**Dr. Azizul Baten**

*Department of Statistics  
Shah Jalal University of Science and Technology  
Sylhet-3114,  
Bangladesh*

**Dr. Bayden R. Wood**

*Australian Synchrotron Program  
Research Fellow and Monash Synchrotron  
Research Fellow Centre for Biospectroscopy  
School of Chemistry Monash University Wellington  
Rd. Clayton,  
3800 Victoria,  
Australia*

**Dr. G. Reza Balali**

*Molecular Mycology and Plant Pathology  
Department of Biology  
University of Isfahan  
Isfahan  
Iran*

**Dr. Beatrice Kilel**

*P.O Box 1413  
Manassas, VA 20108  
USA*

**Prof. H. Sunny Sun**

*Institute of Molecular Medicine  
National Cheng Kung University Medical College  
1 University road Tainan 70101,  
Taiwan*

**Prof. Ima Nirwana Soelaiman**

*Department of Pharmacology  
Faculty of Medicine  
Universiti Kebangsaan Malaysia  
Jalan Raja Muda Abdul Aziz  
50300 Kuala Lumpur,  
Malaysia*

**Prof. Tunde Ogunsanwo**

*Faculty of Science,  
Olabisi Onabanjo University,  
Ago-Iwoye.  
Nigeria*

**Dr. Evans C. Egwim**

*Federal Polytechnic,  
Bida Science Laboratory Technology Department,  
PMB 55, Bida, Niger State,  
Nigeria*



**Prof. George N. Goulielmos**

*Medical School,  
University of Crete  
Voutes, 715 00 Heraklion, Crete,  
Greece*

**Dr. Uttam Krishna**

*Cadila Pharmaceuticals Limited,  
India 1389, Tarsad Road,  
Dholka, Dist: Ahmedabad, Gujarat,  
India*

**Prof. Mohamed Attia El-Tayeb Ibrahim**

*Botany Department, Faculty of Science at Qena,  
South Valley University, Qena 83523,  
Egypt*

**Dr. Nelson K. Ojijo Olang'o**

*Department of Food Science & Technology,  
JKUAT P. O. Box 62000, 00200, Nairobi,  
Kenya*

**Dr. Pablo Marco Veras Peixoto**

*University of New York NYU College of Dentistry  
345 E. 24th Street, New York, NY 10010  
USA*

**Prof. T E Cloete**

*University of Pretoria Department of  
Microbiology and Plant Pathology,  
University of Pretoria,  
Pretoria,  
South Africa*

**Prof. Djamel Saidi**

*Laboratoire de Physiologie de la Nutrition et de  
Sécurité  
Alimentaire Département de Biologie,  
Faculté des Sciences,  
Université d'Oran, 31000 - Algérie  
Algeria*

**Dr. Tomohide Uno**

*Department of Biofunctional chemistry,  
Faculty of Agriculture Nada-ku,  
Kobe., Hyogo, 657-8501,  
Japan*

**Dr. Ulises Urzúa**

*Faculty of Medicine,  
University of Chile Independencia 1027, Santiago,  
Chile*

**Dr. Aritua Valentine**

*National Agricultural Biotechnology Center,  
Kawanda  
Agricultural Research Institute (KARI)  
P.O. Box, 7065, Kampala,  
Uganda*

**Prof. Yee-Joo Tan**

*Institute of Molecular and Cell Biology 61 Biopolis  
Drive,  
Proteos, Singapore 138673  
Singapore*

**Prof. Viroj Wiwanitkit**

*Department of Laboratory Medicine,  
Faculty of Medicine, Chulalongkorn University,  
Bangkok  
Thailand*

**Dr. Thomas Silou**

*Universit of Brazzaville BP 389  
Congo*

**Prof. Burtram Clinton Fielding**

*University of the Western Cape  
Western Cape,  
South Africa*

**Dr. Brnčić (Brncic) Mladen**

*Faculty of Food Technology and Biotechnology,  
Pierottijeva 6,  
10000 Zagreb,  
Croatia.*

**Dr. Meltem Sesli**

*College of Tobacco Expertise,  
Turkish Republic, Celal Bayar University 45210,  
Akhisar, Manisa,  
Turkey.*

**Dr. Idress Hamad Attitalla**

*Omar El-Mukhtar University,  
Faculty of Science,  
Botany Department,  
El-Beida, Libya.*

**Dr. Linga R. Gutha**

*Washington State University at Prosser,  
24106 N Bunn Road,  
Prosser WA 99350-8694.*

**Dr Helal Ragab Moussa**

*Bahnay, Al-bagour, Menoufia,  
Egypt.*

**Dr VIPUL GOHEL**

*DuPont Industrial Biosciences  
Danisco (India) Pvt Ltd  
5th Floor, Block 4B,  
DLF Corporate Park  
DLF Phase III  
Gurgaon 122 002  
Haryana (INDIA)*

**Dr. Sang-Han Lee**

*Department of Food Science & Biotechnology,  
Kyungpook National University  
Daegu 702-701,  
Korea.*

**Dr. Bhaskar Dutta**

*DoD Biotechnology High Performance Computing  
Software Applications  
Institute (BHSAI)  
U.S. Army Medical Research and Materiel  
Command  
2405 Whittier Drive  
Frederick, MD 21702*

**Dr. Muhammad Akram**

*Faculty of Eastern Medicine and Surgery,  
Hamdard Al-Majeed College of Eastern Medicine,  
Hamdard University,  
Karachi.*

**Dr. M. Muruganandam**

*Department of Biotechnology  
St. Michael College of Engineering & Technology,  
Kalayarkoil,  
India.*

**Dr. Gökhan Aydın**

*Suleyman Demirel University,  
Atabey Vocational School,  
Isparta-Türkiye,*

**Dr. Rajib Roychowdhury**

*Centre for Biotechnology (CBT),  
Visva Bharati,  
West-Bengal,  
India.*

**Dr Takuji Ohyama**

*Faculty of Agriculture, Niigata University*

**Dr Mehdi Vasfi Marandi**

*University of Tehran*

**Dr Fügen DURLU-ÖZKAYA**

*Gazi University, Tourism Faculty, Dept. of  
Gastronomy and Culinary Art*

**Dr. Reza Yari**

*Islamic Azad University, Boroujerd Branch*

**Dr Zahra Tahmasebi Fard**

*Roudehen branche, Islamic Azad University*

**Dr Albert Magrí**

*Giro Technological Centre*

**Dr Ping ZHENG**

*Zhejiang University, Hangzhou, China*

**Dr. Kgomotso P. Sibeko**

*University of Pretoria*

**Dr Greg Spear**

*Rush University Medical Center*

**Prof. Pilar Morata**

*University of Malaga*

**Dr Jian Wu**

*Harbin Medical University, China*

**Dr Hsiu-Chi Cheng**

*National Cheng Kung University and Hospital.*

**Prof. Pavel Kalac**

*University of South Bohemia, Czech Republic*

**Dr Kürsat Korkmaz**

*Ordu University, Faculty of Agriculture,  
Department of Soil Science and Plant Nutrition*

**Dr. Shuyang Yu**

*Department of Microbiology, University of Iowa  
Address: 51 newton road, 3-730B BSB bldg. Iowa  
City, IA, 52246, USA*

**Dr. Binxing Li**

**Dr. Mousavi Khaneghah**

*College of Applied Science and Technology-  
Applied Food Science, Tehran, Iran.*

**Dr. Qing Zhou**

*Department of Biochemistry and Molecular  
Biology,  
Oregon Health and Sciences University Portland.*

**Dr Legesse Adane Bahiru**

*Department of Chemistry,  
Jimma University,  
Ethiopia.*

**Dr James John**

*School Of Life Sciences,  
Pondicherry University,  
Kalapet, Pondicherry*

# Instructions for Author

**Electronic submission** of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

The **cover letter** should include the corresponding author's full address and telephone/fax numbers and should be in an e-mail message sent to the Editor, with the file, whose name should begin with the first author's surname, as an attachment.

## Article Types

Three types of manuscripts may be submitted:

**Regular articles:** These should describe new and carefully confirmed findings, and experimental procedures should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.

**Short Communications:** A Short Communication is suitable for recording the results of complete small investigations or giving details of new models or hypotheses, innovative methods, techniques or apparatus. The style of main sections need not conform to that of full-length papers. Short communications are 2 to 4 printed pages (about 6 to 12 manuscript pages) in length.

**Reviews:** Submissions of reviews and perspectives covering topics of current interest are welcome and encouraged. Reviews should be concise and no longer than 4-6 printed pages (about 12 to 18 manuscript pages). Reviews are also peer-reviewed.

## Review Process

All manuscripts are reviewed by an editor and members of the Editorial Board or qualified outside reviewers. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review.

Decisions will be made as rapidly as possible, and the journal strives to return reviewers' comments to authors as fast as possible. The editorial board will re-review manuscripts that are accepted pending revision. It is the goal of the AJFS to publish manuscripts within weeks after submission.

## Regular articles

All portions of the manuscript must be typed double-spaced and all pages numbered starting from the title page.

**The Title** should be a brief phrase describing the contents of the paper. The Title Page should include the authors' full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

**The Abstract** should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 10 key words that will provide indexing references should be listed.

A list of non-standard **Abbreviations** should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml). Standard abbreviations (such as ATP and DNA) need not be defined.

**The Introduction** should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

**Materials and methods** should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer's name and address. Subheadings should be used. Methods in general use need not be described in detail.

**Results** should be presented with clarity and precision. The results should be written in the past tense when describing findings in the authors' experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.

**The Discussion** should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

**The Acknowledgments** of people, grants, funds, etc should be brief.

**Tables** should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph form or repeated in the text.

**Figure legends** should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or Powerpoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

**References:** In the text, a reference identified by means of an author's name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author's name should be mentioned, followed by 'et al'. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like 'a' and 'b' after the date to distinguish the works.

Examples:

Abayomi (2000), Agindotan et al. (2003), (Kelebeni, 1983), (Usman and Smith, 1992), (Chege, 1998;

1987a,b; Tijani, 1993,1995), (Kumasi et al., 2001) References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.

Examples:

Chikere CB, Omoni VT and Chikere BO (2008). Distribution of potential nosocomial pathogens in a hospital environment. *Afr. J. Biotechnol.* 7: 3535-3539.

Moran GJ, Amii RN, Abrahamian FM, Talan DA (2005). Methicillinresistant *Staphylococcus aureus* in community-acquired skin infections. *Emerg. Infect. Dis.* 11: 928-930.

Pitout JDD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey M, Laupland KB (2007). Molecular epidemiology of CTXM-producing *Escherichia coli* in the Calgary Health Region: emergence of CTX-M-15-producing isolates. *Antimicrob. Agents Chemother.* 51: 1281-1286.

Pelczar JR, Harley JP, Klein DA (1993). *Microbiology: Concepts and Applications.* McGraw-Hill Inc., New York, pp. 591-603.

### Short Communications

Short Communications are limited to a maximum of two figures and one table. They should present a complete study that is more limited in scope than is found in full-length papers. The items of manuscript preparation listed above apply to Short Communications with the following differences: (1) Abstracts are limited to 100 words; (2) instead of a separate Materials and Methods section, experimental procedures may be incorporated into Figure Legends and Table footnotes; (3) Results and Discussion should be combined into a single section.

Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage.

**Fees and Charges:** Authors are required to pay a \$650 handling fee. Publication of an article in the African Journal of Biotechnology is not contingent upon the author's ability to pay the charges. Neither is acceptance to pay the handling fee a guarantee that the paper will be accepted for publication. Authors may still request (in advance) that the editorial office waive some of the handling fee under special circumstances

**Copyright: © 2015, Academic Journals.**

All rights Reserved. In accessing this journal, you agree that you will access the contents for your own personal use but not for any commercial use. Any use and or copies of this Journal in whole or in part must include the customary bibliographic citation, including author attribution, date and article title.

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.

**Disclaimer of Warranties**

In no event shall Academic Journals be liable for any special, incidental, indirect, or consequential damages of any kind arising out of or in connection with the use of the articles or other material derived from the AJB, whether or not advised of the possibility of damage, and on any theory of liability.

This publication is provided "as is" without warranty of any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Descriptions of, or references to, products or publications does not imply endorsement of that product or publication. While every effort is made by Academic Journals to see that no inaccurate or misleading data, opinion or statements appear in this publication, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Academic Journals makes no warranty of any kind, either express or implied, regarding the quality, accuracy, availability, or validity of the data or information in this publication or of any other publication to which it may be linked.

**ARTICLES**

**Molecular cloning and expression of a novel gene related to legume lectin from *Salvia miltiorrhiza* Bunge**

Wenping Hua, Limin Han and Zhezhi Wang

**Molecular screening for erythromycin resistance genes in *Streptococcus pyogenes* isolated from Iraqi patients with tonsilo-pharyngites**

Hassan N. Ali, Maysaa A. R. Dhahi and Abdul Kareem H. Abd

**Antifungal, acute toxicity and mutagenicity activity of extracts from *Datura stramonium*, *Jacquinia macrocarpa* and *Krameria erecta* on *Fusarium verticillioides***

M. P. Frías-Escalante, A. Burgos-Hernández, M. Plascencia-Jatomea, M. L. Aldana-Madrid and M. O. Cortez-Rocha

**Connecting DNA origami structures using the biotin-streptavidin specific binding**

Amoako George, Ming Zhou, Rian Ye, Mensah-Amoah Patrick, Twum Anthony and Sam Frederick

**Reproductive performance of dairy cows affected by endometritis, pododermatitis and mastitis**

Thaiza Campos Marques, Karen Martins Leão, Moraima Castro Rodrigues, Natalia do Carmo Silva and Rossane Pereira da Silva

## Full Length Research Paper

# Molecular cloning and expression of a novel gene related to legume lectin from *Salvia miltiorrhiza* Bunge

Wenping Hua<sup>1,2</sup>, Limin Han<sup>1,2</sup> and Zhezhi Wang<sup>2\*</sup><sup>1</sup>Department of Life Sciences, Shaanxi Xueqian Normal University, Xi'an, Shaanxi 710061, P.R. China.<sup>2</sup>Key Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an 710062, P.R. China.

Received 19 December, 2013; Accepted 13 July, 2015

Lectins have been well studied and proved to play important roles in plant defense but information of legume lectins from non-legume plants has been rarely reported. A new legume lectin gene, designated as *SmL1*, was cloned from *Salvia miltiorrhiza* Bunge, a famous traditional Chinese medicinal plant. The cDNA of *SmL1* was 919 bp in length and contained an 822 bp open reading frame (ORF) encoding a putative lectin precursor with two legume lectin domains. The deduced SML1 protein of *SmL1* shared 29 to 43% identities with other legume lectin sequences. Real time PCR analysis revealed that *SmL1* was predominantly expressed in the leaves and could be induced by pathogens and MeJA. The recombinant protein (rSmL1) of *SmL1* in *Escherichia coli* M15 was purified and showed agglutination activity towards rabbit and mouse red blood cells, and anti-bacterial activity against *E. coli* (ATCC35218), *Pseudomonas lachrymans* (PSL) and *Xanthomonas campestris* pv. *Campestris* (Pammel) Dowson (XC-1). Based on these results, *SmL1* could play a role in medicinal plant disease control.

**Key words:** Anti-bacterial activity, gene expression, legume lectin, recombinant protein, *Salvia miltiorrhiza* Bunge.

## INTRODUCTION

Plant lectins or agglutinins are a large group of proteins, which possess at least one non-catalytic domain that binds reversibly to a specific mono- or oligosaccharide (Carlini and Grossi-de-Sa, 2002; Peumans and Van Damme, 1995). Lectins exist in most living organisms but were first identified as plant proteins that agglutinate human red blood cells (Van Damme et al., 1998). Now thousands of plant lectins were found and stored in the

Lectin database (Lectindb, <http://proline.physics.iisc.ernet.in/cgi-bin/lectindb/>). Based on their different carbohydrate-binding specificities, plant lectins have been divided into 12 different families, such as (1) *Agaricus bisporus* agglutinin homologs, (2) Amaranthins, (3) Class V chitinase homologs with lectin activity, (4) Cyanovirin family, (5) EEA family, (6) GNA family, (7) proteins with hevein domains, (8) Jacalins, (9) proteins with legume

\*Corresponding author. E-mail: zzwang@snnu.edu.cn. Tel: +86-29-85310260. Fax: +86-29-85310546.

**Abbreviations:** EAPL, Extralong autumn purple bean; WGA, wheat germ agglutinin; ORF, open reading frame.

Author(s) agree that this article remains permanently open access under the terms of the [Creative Commons Attribution License 4.0 International License](http://creativecommons.org/licenses/by/4.0/)



lectin domains, (10) LysM domain, (11) Nictaba family (formerly Cucurbitaceae phloem lectins), and (12) Ricin-B family (Van Damme et al., 2008). It has been suggested that plant lectins play important roles due to their abundance in the immune defence, and also that lectins have been coopted to adapt for several functions during evolution (Charungchittrak et al., 2011). More and more attention has been drawn onto the antimicrobial activity of plant lectins. Many lectins had been found with antimicrobial activity, such as lectins derived from *Phthirusa pyrifolia* leaves (Costa et al., 2010), *Eugenia uniflora* (EuniSL) (Oliveira et al., 2008) and *Myracrodruon urundeuva* (Sá et al., 2009). In recent years, even some lectins have anti-viral activity, such as lectin from seeds of *Phaseolus vulgaris* L. cv. Extralong Autumn Purple Bean (EAPL) and BanLec isolated from the fruit of bananas, indicated Anti-HIV-1 activities (Fang et al., 2010; Swanson et al., 2010). Some of them, such as a wheat germ agglutinin (WGA) (Ciopraga et al., 1999), Concanavalin A (Safina et al., 2008), *Sebastiania jacobinensis* bark lectin (SejaBL) (Vaz et al., 2010) and *P. pyrifolia* leaf lectin (Costa et al., 2010), have been tried to biologically control plant diseases.

However, different families of plant species, as well as different tissues within the same plant, can contain different lectins with different bioactivities, including different carbohydrate-binding specificities and antimicrobial activity (Charungchittrak et al., 2011). They occur widely in plants but manifest significant differences in bioactivities, which means only a few of them has application prospect. Presently, most of their functions are still unclear in many plants. *Salvia miltiorrhiza* Bunge is a well-known medicinal plant in the Labiatae family. Its dry roots or rhizomes (called 'danshen' or 'tanshen' in China, but better known in the west as Chinese sage or red sage root) has been used in the treatment of cardiovascular, cerebrovascular, hyperlipidemia, and acute ischemic stroke diseases for decades (Kang et al., 2003; Yang et al., 2006; Zhong et al., 2009). One soil-borne disease induced by *Fusarium solani* could lead to rotten roots of *S. miltiorrhiza*, which results in the reduction of yields and the decline of quality. In recent years, the incidence of diseased plants in the field has varied from 10 to 30% in its growth zones. It is difficult to control this disease by farm chemicals, which may pollute this medicinal crop and its environment if applied irrationally. Biocontrol means has attracted people's attention in sustainable environmental development to control this disease compared to the application of chemicals.

To explore the potential lectin protein-encoding genes, we screened our cDNA library of *S. miltiorrhiza* (Hua et al., 2011) and found 30 unigenes encoding putative lectin proteins. Contig1927 (one of lectin unigenes) has also been reported as the highest abundance gene in *S. miltiorrhiza* root EST library (Li et al., 2010). Taking into account that the roots are the part of occurrence of rotten root in *S. miltiorrhiza*, we chose this gene as our object in

the present paper. Firstly, we cloned and characterized this novel gene (GenBank Accession Number: EF593952), then we over-expressed it in *Escherichia coli*, eventually its agglutination and antibacterial activity had been identified *in vitro*. The purified recombinant protein showed significant anti-bacterial activity against *E. coli* (ATCC35218), *Pseudomonas lachrymans* and *Xanthomonas campestris* pv. *Campestris* (Pammel) Dowson. Therefore, these results suggested that the application of this gene in genetically modified plants may be an efficient way to control root rot in *S. miltiorrhiza* and generate more profitable and productive yields without affecting environment.

## MATERIALS AND METHODS

### Plant materials

The seeds of *S. miltiorrhiza* Bunge were collected from Shangluo County, Shaanxi Province, China. The plants were grown in pots with soil in greenhouse under normal irrigation and fertilization. Two-month-old seedlings were used for DNA extraction and the following two treatments, respectively. For the methyl jasmonate (MeJA) treatment, leaves were sprayed with 5  $\mu$ M MeJA. Then samples were collected at hour 0, 1, 6, 12, 24 and 48 h after MeJA application. Young leaves nicked with a knife were infected by *P. lachrymans* (PSL,  $10^8$  cfu·ml<sup>-1</sup>), and collected at 0, 24, 48, 72 and 96 h post-infection. All collected samples were frozen immediately in liquid nitrogen and stored at -80°C before use.

### Isolation of the lectin gene

The genomic DNA was extracted from *S. miltiorrhiza* by CTAB based method (Beji et al., 1987). Total RNAs were extracted respectively from the roots, stems and leaves of control and treated plantlets, using BIOZOL Reagent (BIOER, China) according to the manufacturer's instructions. The first strand cDNA was synthesized using Revert Aid First Strand cDNA Synthesis Kit (MBI, Fermentas). The lectin gene was amplified with the forward primer: 5'-ATGGCCAAGCTTCTCCAAAAC-3' and the reverse primer: 5'-GTCGATCGCTTAGTCCTTATTGA-3', both of which were designed according to unigene sequence (Contig1927) from cDNA library of *S. miltiorrhiza*. The PCR reaction was performed under the following conditions: genomic DNA or cDNA was denatured at 94°C for 4 min followed by 30 cycles of amplification (94°C for 30 s, 54°C for 30 s and 72°C for 80 s) and then extension at 72°C for 10 min. The PCR fragments were purified by DNA Gel Extraction Kit (Biospin) and inserted into pGMT-Easy T vector (Promega, USA) and sequenced.

### Expression level of *Sml1* gene in different tissues

SYBR Green II dye (Takara, Japan) was used for detecting the expression levels of *Sml1* under various treatments or in different tissues of *S. miltiorrhiza*. Real-time PCR was conducted with an iQ™5 Multicolor Real-Time PCR Detection System (Bio-Rad). The *Sml1* was amplified with the forward primer: 5'-CATGACATC GTCTCGTGGTATTTTC-3' and the reverse primer: 5'-GATCGCTTAGTCCTTAT TGATTTGC-3'. A housekeeping gene, *SmGAPDH* (glyceraldehydes-3-phosphate dehydrogenase, CV170251), was used as our control and was amplified with forward primer GAPF 5'-CCACCGTCCACTCCATCACT-3' and

reverse primer GAPR (5'-TG GGAAGCTCGGAACGACATAC-3'). The amplification of *SmL1* and *SmGAPDH* gene was performed as: cDNA was denatured at 95°C for 5 min followed by 40 cycles of amplification (95°C for 10 s, 59°C for 15 s and 70°C for 10 s to collected fluorescence). The products were validated by electrophoresis on a 1.5% agarose gel then further sequenced for confirmation. Expression was quantified by the comparative  $C_T$  method (Vandesompele et al., 2002). Each data point represented the average of three separate experiments. Statistical analysis was done with SPSS 13.0 software. One-way analysis of variance (ANOVA) and Tukey's pair-wise comparison tests ( $P < 0.05$ ) were successively performed to determine significant differences between means.

### Construction of lectin expression vector

The mature protein-encoding region was amplified using the forward primer: 5'-GGGGTACCCAAACGACGTCCTTCACCTA-3' containing a *KpnI* restriction site (underlined) and the reverse primer 5'-AACTGCAAGTCGATCGCTTAGTCC TTATTGA-3' containing a *PstI* restriction site (underlined). The amplification condition was as described previously. The PCR product digested with *KpnI* and *PstI* was ligated with pQE30 vector using T4 DNA ligase (TaKaRa), and then transformed into *E. coli* M15 strain. Positive transformants were screened by plating on Luria-Bertani (LB) agar containing kanamycin and ampicillin antibiotics after growing overnight at 37°C.

### *SmL1* gene expression and purification

The positive M15 cells were cultured in LB medium containing 100 mg/ml ampicillin and 50 mg/ml kanamycin at 37°C to an absorbance of 0.6 to 0.8 at 600 nm. 1 mM IPTG were applied into culture to induced target gene expression. The cells for SDS-PAGE were harvested at 0, 1, 2, 3, 4, 5 and 6 h after induction, then centrifuged at 4°C, 4,000 g for 8 min. Afterwards, the pellet with 6 h induction was re-suspended in PBS buffer (containing 8 M urea), then the cell walls were fractured by ultrasound (400 w for 7 min). After another centrifuge at 4°C, 10,000 g for 20 min, the supernatant was collected for protein purification using equilibrated His-bond Ni Affinity Resin column (Zhuoguan, China) according to the manufacturer's instructions. The elutions were analyzed by SDS-PAGE.

### Agglutination activity test of recombinant protein of *SmL1* gene

The erythrocytes from rabbit and mouse (pre-treated with trypsin) were washed with normal saline (0.9%) for three times. The recombinant protein (0.5 mg/ml) solution was serially diluted with two-fold increments. Agglutination assays were carried out in a 96-U-well plate in a final volume of 50  $\mu$ l containing 25  $\mu$ l the diluted recombinant protein solutions and 25  $\mu$ l of a 1% suspension of red blood cells. Elution/washing buffer of the recombinant protein and normal saline were considered negative controls. Agglutination was assessed visually after 2 h at room temperature using microscope. Two separate experiments for every individual were performed and the means were calculated.

### Anti-bacterial activity of recombinant protein of *SmL1* (rSmL1) gene

The anti-bacterial activity of rSmL1 was qualitatively evaluated by optical density. *E. coli* (ATCC35218), PSL, and XC-1 were bought

from China General Microbiological Culture Collection Center as test bacteria. The test bacteria were incubated at 28°C for PSL and XC-1, at 37°C for *E. coli* (ATCC35218) overnight at 180 rpm. A secondary propagation of the cells was carried out for another 2 to 3 h, then cultures were divided into equal parts (50 ml for each). Equal amount of purified rSmL1 protein was added into each culture, and boiled purified protein was used as negative control. After inoculation of purified recombinant rSmL1, the density of each medium was measured at OD 595 nm after 0, 1, 2, 3, 4 and 5 h. The experiments were done three times. The *E. coli*, PSL, and XC-1 were cultured in Ordinary Broth Medium at 37°C, KB medium without agar at 28°C, and modified Broth Medium containing sucrose (10 g/L) at 28°C, respectively. Significant differences between treatment and control groups were analyzed using one-way ANOVA with SPSS13.0 software.

## RESULTS AND DISCUSSION

### Isolation and sequence analysis of *SmL1*


The full-length cDNA of *SmL1* was amplified by RT-PCR. The cDNA fragment was 919 bp in length and contained an 822 bp open reading frame (ORF) positioned from 33 to 855 bp (Figure 1a). The ORF of *SmL1* encodes 273 amino acids with the isoelectric point of 5.00 and molecular mass of 29.2 kDa. No intron was found in *SmL1* sequence by comparing genomic and cDNA sequences. The deduced amino acids sequence (named as SmL1) had two legume lectin domains, a lectin-legB (amino acids 28 to 203) domain, and a lectin-legA (amino acids 211 to 256) domain according to BLASTp search against NCBI (Figure 1b). The amino acid number and molecular mass were identical with other legume lectins as previously reported (Etzler, 1985; Sharon and Lis, 1990; Van Damme et al., 1998). Protein-protein BLAST of deduced *SmL1* amino acid sequence showed 29 to 43% identities and 49 to 61% positives in local alignments against candidate genes from *Arachis hypogaea* (ABJ15831), *Sophora flavescens* (AF285121), *Sophora alopecuroides* (AAA74572), *Glechoma hederacea* (AAN 050977), *Canavalia ensiformis* (CAA25787), *Cladrastis kentukea* (Q39529), *Sophora japonica* (AAB51442) and *Phaseolus leptostachyus* (CAH60215). All these results suggested that SmL1 belonged to legume lectin family.

Most legume lectins are extensively distributed in legume plants. However, Gleheda (AAN05097) (a legume lectin isolated from *G. hederacea*) and SBoL (a *Salvia bogotensis* seed lectin) had been identified from non-legumes (Vega and Pérez, 2006; Wang et al., 2003) and some of which has been shown to have important physiological activity in plants, such as Gleheda, which indicate insecticidal activity against Colorado potato beetle larvae (Wang et al., 2003). To our knowledge, this is the first time to report legume lectin gene in *S. miltiorrhiza*. And our lectin gene encoding protein sequence was similar to Gleheda, which indicated that it may also played unusual roles in physiology in

```

CTGCAGGAATTGGCACGAGGCTCAATTAAGCCATGGCCAAAGCTTCTCCAAAACCTAATTCTCTTCTCTCC 72
      N A K L L Q N L I P L L S
GCCATCGTCTCTCTCTCGCCGCTGCCAACACGGTGGCGGTCCCAAAGAGCTCTTCACTACGACTTCTGG 144
A I V L L L A A A N T V R S↓Q T T S F T Y D F W
GGGACCCAGCCGAAAGATCTCATCTATCAAGGCTCCGCCCATTTCCCGTGGAGCACCACTTCTCTCCGCTC 216
G D Q P K D L I Y Q G S A H F P S S T T F L R L
ACCGAGCACTATCTCTACAAGTCCGCGGGTGGTGCACCTCGAACCCGGTCCAGTTCCTCCAAAGGGGGAAAC 288
T D A L S S Q V G R V V H S N P V Q F S Q G G N
CAAGTCGACTTTGAAACCACCGTGAACCTTCATCATCACCCCGCCCGCCGACAACACCCCTGCCGATGGCCTC 360
Q V D F E T T V N F I I T P G P D N T P A D G L
GCCTTCTTCATGCCCCCGTGGCAACCACCGCCCTACTGGCTCCAAAGGAGCCAACTCGGAGTCTTTGAA 432
A F F I A P V G T T A P T G S N G A N L G V F E
TCCAAAGGCAACGGCGCCCGGGTCTTTGCCGTGGAAGTCGACACCTACGTCAAAGCGCGGTGGGATCCGCTC 504
S N G N G A A V F A V E V D T Y V N G A W D P L
TATCCCCACATCGGCATCGACATCGGCTCTAGGGCATCCAGCAACAGCGCAGGTGACAGCTCCATACTC 576
Y P H I G I D I G S R A S S N T T Q V D S S I L
GGGCAGCAGGTGACTCTGTGATCAACTACGTGGAGCCACGAGGATGATCACCGCCAAAGTCACCGCCGCG 648
G Q Q V T L L I N Y V G A T R N I T A K V T A G
TCGAAGACGTTTGAGGTCAGCTATGAGTACGATTTGAGCGACTTTGTTACTGAGCAGGTTTCAGGTCCGGCTA 720
S K T F E V S Y E Y D L S D F V T E Q V Q V G L
TCCGCTCCACCGGACAACACGTGCCACCCATGACATCGTCTCGTGGTATTTACCGCCACCATGGTGCAG 792
S A S T G Q H V A T H D I V S W Y F T A T N V Q
TCAAAGCCCGTCCGAGGAGCAGGAAGGAGCTGCCCGGAAACATTATTCGTCAGTITGTTGATTTTGTGAT 864
S K A V A R S R K E L A G N I I R Q F V *
GTGTGTGTGTATGTGTGCATGTGTGTCCAAATCAATAAGGACTAAGCGATCGAC 919
    
```

**Figure 1a.** The full-length cDNA sequence and deduced amino acid sequence of *S. miltiorrhiza* lectin (*SmL1*). The star codon (ATG) and the stop codon are shown by boxes. The putative processing sites for the cleavage of in C-terminal are marked by arrow. The putative N-glycosylation site is shown by black ground.




**Figure 1b.** Putative conserved domain has been detected with the protein-protein BLAST tool of NCBI.

*S. miltiorrhiza* as Gleheda in *G. hederacea*.

The signal peptide (SignalP, <http://www.cbs.dtu.dk/services/SignalP/>) prediction on *SmL1* revealed a single peptide cleavage site between position 27 and 28th amino acid residues (Ser-Gln) (Figure 1a). The cleavage of the signal peptide in C-terminal sequence of *SmL1* resulted in a lectin polypeptide of approximately 26.3 kDa with theoretical pI 4.76.

### Sequence analysis of *SmL1*


Multi-alignment of *SmL1* with other legume lectins (Figure 1) was conducted by ClustalW (Figure 2a). *SmL1* showed 43, 37, 37 and 37% identity to protein sequences of Gleheda, *S. alopecuroides* lectin, *S. flavescens* lectin, and LecCIAll (*C. kentukea* agglutinin), respectively. A further examination on the sequences of *SmL1*, Gleheda,



**Figure 2a.** Multiple sequence alignment of SmL1 with other legume lectin. The multiple sequence alignment was performed by Clustal W (<http://www.ebi.ac.uk/clustalw/index.html>): *C. kentukeya* Agglutinin (Q39529); *S. japonicum* (AAB51442); *S. alopecuroides* lectin (AAA74572); *S. flavescens* (AF285121); *A. hypogaea* (ABJ 15831); *C. ensiformis* (CAA25787); *P. leptostachyus* (CAH60215); *G. hederacea* lectin (AAN050 977); *S. miltiorrhiza* (EF593952).

*S. flavescens* lectin, and *A. hypogaea* lectin, indicated that the residues forming the mono-saccharide binding sites were highly conserved. The putative carbohydrates

binding sites in SmL1 were found as: Asp<sub>107</sub>, Ala<sub>139</sub>, Asn<sub>151</sub>, Gly<sub>234</sub>, Gln<sub>235</sub> and His<sub>236</sub> (Figure 1a). Asp<sub>107</sub>, Asn<sub>151</sub>, Gly<sub>234</sub> were identical to Gleheda, Gln<sub>235</sub> was



**Figure 2b.** The phylogenetic relationships of SmL1 with other related proteins. The tree was constructed the alignment resulting from analysis by MEGA4.0.

identical with *S. flavescens* lectin and *A. hypogaea* lectin (Liu et al., 2008). Ala<sub>139</sub> in SmL1 was replaced by Gly<sub>93</sub> compared to Gleheda (Wang et al., 2003). Some amino acid residues of monomer ConA (a classical legume lectin from *C. ensiformis*) and legume lectin LoLI from *L. odoratus* L. were highly conserved, which decided the sorts of binding carbohydrate, such as Asp<sub>81</sub>, Gly<sub>99</sub>, Asn<sub>125</sub>, Gly<sub>208</sub>, Ala<sub>208</sub> and Glu<sub>210</sub> in LoLI protein. Asp<sub>81</sub> and Asn<sub>125</sub> in LoLI were consistent in all known legume lectins, and necessary for carbohydrate activity; while other amino acid residues, Ala<sub>209</sub> and Glu<sub>210</sub> (LoLI), were alterable, probably participated in binding carbohydrate (Bourne et al., 1990; Perçin et al., 2012). Some amino acid residues (Asp<sub>107</sub>, Asn<sub>151</sub>) of the putative conservative carbohydrates binding sites in SmL1 were invariant, while Ala<sub>139</sub> and His<sub>236</sub> were different from other legume lectins, just like ConA and LoLI (Sharon and Lis, 1990).


Furthermore, the phylogenetic relationship of SmL1 with other candidates was determined. The phylogenetic tree was constructed by neighbor-joining method with MEGA 4.0. It shows the SmL1 and Gleheda were clustered into one sub-group; other lectins from legume plants were clustered into another sub-group but SmL1 was closer to legume lectins than Gleheda in molecular evolution (Figure 2b). The amino acid residues on carbohydrate-binding site (in comparison with Gly<sub>93</sub> in Gleheda, Ala<sub>139</sub> in SmL1 were more conserved among legume lectins) also supported our assumption. The identification of *SmL1* gene from *S. miltiorrhiza* showed high similarity with Gleheda, provided another direct evidence that the possibility of finding an ortholog of legume lectins gene outside the family Fabaceae (Wang et al., 2003), which also indicated the evolutionary processes of the same ancestor of modern legume lectins.

### Tertiary structure prediction of *SmL1* amino acid sequence


According to the deduced amino acid sequence of *SmL1* gene, the three-dimensional model of SmL1 was constructed using SWISS-MODEL (<http://swissmodel.expasy.org/>) (Figure 3). The model indicated that the SmL1 monomer consisted of two  $\beta$ -sheets, a curved seven-stranded  $\beta$ -sheet forming the front face, and a flattened six-stranded  $\beta$ -sheet forming the back face of the monomer, which interconnected by turns and loops. Additionally, a four-stranded  $\beta$ -sheet, referred as the S-sheet, was occurred between the two  $\beta$ -sheets at the top of the monomer. The model also showed SmL1 can bind calcium and manganese ions, which could keep the amino acid residues of the sugar-binding site at the required positions (Roopashree et al., 2006). Like other legume lectins (Loris et al., 1998; Sharon and Lis, 1990; Varrot et al., 2011),  $\beta$ -sheets in SmL1 are dominated structure, whereas  $\alpha$ -helices are virtually absent. Therefore, it can be concluded that SmL1 adopts the same  $\beta$ -sandwich structure as the classical legume lectins (Wang et al., 2003). Most known legume lectins are homodimers or homotetramers (Li et al., 2012). One monomer cannot form the complex structure with carbohydrates (Eijsden et al., 1992; Li et al., 2012), whether the SmL1 is homodimers or homotetramers still need to be further elucidated.

### Expression patterns of *SmL1* in *S. miltiorrhiza*

According to the report of Li et al. (2010) *SmL1* have a very high expression level in the *S. miltiorrhiza* root (2010). However, our results of real-time PCR shows that



**Figure 3.** Tertiary structure prediction of *SmL1* amino acid sequence. **A.** flattened six-stranded  $\beta$ -sheet. **B.** Seven-stranded  $\beta$ -sheet, **C.** The S-sheet. The red fragments on the backbone show the putative carbohydrates binding sites.



**Figure 4.** Result of the real-time PCR shows *SmL1* gene expression in different tissues (**A**) or under different treatments (**B**) PSL, (**C**) MeJA). Bars with the same lowercase letter are not significantly different ( $P > 0.05$ ).

the expression level of *SmL1* was expressed highly in leaves, and but low in stems and roots. The expression level of *SmL1* in leaves was approximately 4 times as high as that in stems, and little mRNAs was of *SmL1* were detected in roots (Figure 4A). *Glegheda gene* is also predominantly expressed in the leaves, which encoding the closer legume lectin protein of *SmL1* (Wang et al., 2003). This might implied that *SmL1* has high expression

levels in various organs, and plant lectins may have important roles according to their abundance. Many legume lectins were served as defense molecules against insect herbivores and pathogens. And the lectin protein-encoding genes can also be induced by insect attack or pathogen infection. To investigate whether *SmL1* expression can be induced by pathogens, we firstly selected XC-1(a pathogen causing black rot of cabbage)

to infect two-month-old *S. miltiorrhiza* seedlings. After XC-1 infection, *SmL1* expression was induced to the highest level at 12 h, and gradually returned to normal levels within 72 h (Figure 4B). That result indicated that *SmL1* was involved in defense against pathogens in *S. miltiorrhiza*.


Jasmonates, as important signal molecules of plant responses to abiotic and biotic stresses, regulate induced defense mechanisms in plants after insect attack and wound response in general (Wasternack et al., 2006). Moreover, the previous studies had showed that the increase of jasmonate levels and the expression of wound-inducible genes after herbivory is a common phenomenon in many plant systems (Qu et al., 2004; Schmidt et al., 2004; Vandendorre et al., 2009). So, we also further determined the change of *SmL1* transcripts level after exposure to methyl jasmonate (MeJA) a derivative of jasmonates) in *S. miltiorrhiza*. Treatment with MeJA only slightly increased transcripts transcript abundance with expression peaking after at 48 h after treatment, and the maximum peak were only about 1.6-fold higher when compared with the control (Figure 4C). So, we concluded that *SmL1* is mainly involved in response against pathogen and may play a small limited role in defense against insect herbivores.

#### Agglutination and antimicrobial activity test

The result of SDS-PAGE indicated that *SmL1* gene expressed a protein (named as rSmL1) with the molecular weight of about 26.2 kDa (Figure 5), which was identical with the size of *SmL1* mature monomer predicted by bioinformatics method. The agglutination activity assays showed that the recombinant rSmL1 protein could agglutinate mouse and rabbit red blood cells compared to negative control. The minimal concentration required to agglutinate trypsin-treated mouse and rabbit erythrocytes was about 1.99 and 3.91  $\mu\text{g/ml}$ , respectively. Obviously, the agglutination potential of rSmL1 was weaker than ConA (0.98  $\mu\text{g/ml}$ ) and Gleheda (0.22  $\mu\text{g/ml}$ ) (Jiang et al., 2006; Wang et al., 2003). This may be caused by applying more tyrsin in our experiment. The bacterial growth experiments showed that the purified protein could inhibit the growth of *E. coli* (ATCC35218), PLS and XC-1 (Figure 6). When the concentration of recombinated *SmL1* increased to 4  $\mu\text{g/ml}$ , *E. coli* barely showed any growth (Figure 6A and B). Compared to *E. coli*, the inhibition effects to PLS (Figure 6C) and XC-1 (Figure 6D) could be observed when the medium contained 5  $\mu\text{g/ml}$  purified proteins. This also further elucidated its role in the anti-pathogen responses in *S. miltiorrhiza*.

#### Conclusion

Plant lectins have been studied over a century. Legume lectin family is the best known lectin family from plants,



**Figure 5.** SDS-PAGE analysis of recombinant rSmL1 protein. Line 1, protein marker; line 2, the protein induced after 5 h; line 3: the purified protein (rSmL1).


which are usually, but not exclusively, found in the leguminous plants. In recent years, legume lectins also occur in several non-leguminous species, such as *G. hederacea* and *S. bogotensis*. But limited numbers of legume lectins from non-legume plant were reported. Now, we cloned and characterized a legume lectin gene, *SmL1*, which is expresses abundant in *S. miltiorrhiza* root. And *SmL1* can be induced by pathogen. Its purified recombinant protein from *E. coli* showed significant agglutination and antibacterial activity *in vitro*. These facts indicated that the *SmL1* protein might be involved in the defense of plant against pathogen. The application of this gene in future plant genetic modification may be an efficient way to control root rot without damaging the environmental biodiversity.

#### Conflict of interests

The author(s) did not declare any conflict of interest.

#### ACKNOWLEDGMENTS

This work benefited from financial support from the postdoctoral fund of Shaanxi Province, the Natural



**Figure 6.** The purified protein inhibits the growth of bacterium. **A)** The growth states of *E. coli* with 2 μg/ml rSmL1 protein. **B)** The growth states of *E. coli* with 4 μg/ml rSmL1 protein. **C)** The growth states of PSL with 4 μg/ml rSmL1 protein, **D)** is the growth states of XC-1 with 4 μg/ml rSmL1 protein.

Science Foundation of Shaanxi Province, China (Grant No. 2014JQ3105) and the Fundamental Research Funds from Shanxi Province Office of Education (14JK1178).

## REFERENCES

- Beji A, Izard D, Gavini F, Leclerc H, Leseine-Delstanche M, Krembel J, (1987). A rapid chemical procedure for isolation and purification of chromosomal DNA from gram-negative bacilli. *Anal. Biochem.* 162: 18-23.
- Bourne Y, Roussel A, Frey M, Rougé P, Fontecilla-Camps JC, Cambillau C (1990). Three-Dimensionnal structures of complexes of Lathyrus ochrus isolectin I with glucose and mannose: Fine specificity of the monosaccharide-binding site. *Proteins* 8:365-376.
- Carlini CR, Grossi-de-Sa MF (2002). Plant toxic proteins with insecticidal properties. A review on their potentialities as bioinsecticides. *Toxicon* 40:1515-1539.
- Charungchittrak S, Petsom A, Sangvanich P, Karnchanat A (2011). Antifungal and antibacterial activities of lectin from the seeds of *Archidendron jiringa* Nielsen. *Food Chem.* 126:1025-1032.
- Ciopraga J, Gozia O, Tudor R, Brezuica L, Doyle RJ (1999). *Fusarium* sp. growth inhibition by wheat germ agglutinin. *Biochim. Biophys Acta* 1428:424-432.
- Costa RMPB, Vaz AFM, Oliva MLV, Coelho LCBB, Correia MTS, Carneiro-da-Cunha MG (2010). A new mistletoe *Phthirusa pyrifolia* leaf lectin with antimicrobial properties. *Process Biochem.* 45:526-533.
- Eijsden RR, Hoedemaeker FJ, Diaz CL, Lugtenberg BJJ, Sylvia de Pater B, Kijne JW, (1992). Mutational analysis of pea lectin. Substitution of Asn125 for Asp in the monosaccharide-binding site eliminates mannose/glucose-binding activity. *Plant mol. Biol.* 20: 1049-1058.
- Etzler ME (1985). Plant lectins: molecular and biological aspects. *Annu. Rev. Plant Physiol.* 36:209-234.
- Fang EF, Lin P, Wong JH, Tsao SW, Ng TB (2010). A lectin with anti-HIV-1 reverse transcriptase, antitumor, and nitric oxide inducing activities from seeds of *Phaseolus vulgaris* cv. extralong autumn purple bean. *J. Agric. Food Chem.* 58:2221-2229.
- Hua WP, Zhang Y, Song J, Zhao LJ, Wang ZZ (2011). *De novo* transcriptome sequencing in *Salvia miltiorrhiza* to identify genes involved in the biosynthesis of active ingredients. *Genomics* 98:272-279.
- Jiang JF, Han Y, Xing LJ, Xu YY, Xu ZH, Chong K (2006). Cloning and expression of a novel cDNA encoding a mannose-specific jacalin-related lectin from *Oryza sativa*. *Toxicon* 47:133-139.
- Kang DG, Oh H, Chung HT, Lee HS (2003). Inhibition of angiotensin converting enzyme by lithospermic acid B isolated from *Radix Salviae miltiorrhiza* Bunge. *Phytother. Res.* 17:917-920.
- Li T, Yin X, Liu D, Ma X, Lv H, Sun S (2012). Isolation and characterization of a novel lectin with antifungal and antiproliferative



- activities from *Sophora alopecuroides* seeds. *Acta Biochim. Biophys. Sin.* 44(7):606-613.
- Li Y, Sun C, Luo HM, Li XW, Niu YY, Chen SL (2010). Transcriptome characterization for *Salvia miltiorrhiza* using 454 GS FLX. *Yao Xue Xue Bao* (in Chinese) 45:524-529.
- Liu Z, Liu B, Zhang ZT, Zhou TT, Bian HJ, Min MW, Liu Y-H, Chen J, Bao JK (2008). A mannose-binding lectin from *Sophora flavescens* induces apoptosis in HeLa cells. *Phytomedicine* 15:867-875.
- Loris R, Hamelryck T, Bouckaert J, Wyns L (1998). Legume lectin structure. *Biochim. Biophys. Acta* 1383(1): 9-36.
- Oliveira MDL, Andrade CAS, Santos-Magalhães NS, Coelho LCBB, Teixeira JA, Carneiro-da-Cunha MG, Correia MTS (2008). Purification of a lectin from *Eugenia uniflora* L. seeds and its potential antibacterial activity. *Lett. Appl. Microbiol.* 46:371-376.
- Perçin I, Yavuz H, Aksöz E, Denizli A, (2012). Mannose-specific lectin isolation from *Canavalia ensiformis* seeds by PHEMA-based cryogel. *Biotechnol. Prog.* 28(3):756-761
- Peumans WJ, Van Damme E (1995). Lectins as plant defense proteins. *Plant Physiol.* 109:347.
- Qu N, Schittko U, Baldwin IT (2004). Consistency of *Nicotiana attenuata*'s herbivore- and jasmonate-induced transcriptional responses in the allotetraploid species *Nicotiana quadrivalvis* and *Nicotiana clevelandii*. *Plant Physiol.* 135:539-548.
- Roopashree S, Singh SA, Gowda LR, Rao AG (2006). Dual-function protein in plant defence: seed lectin from *Dolichos biflorus* (horse gram) exhibits lipoxygenase activity. *Biochem. J.* 395:629-639.
- Sá R, Gomes F, Napoleão T, Santos N, Melo C, Gusmão N, Coelho L, Paiva P, Bieber L (2009). Antibacterial and antifungal activities of *Myracrodruon urundeuva* heartwood. *Wood Sci. Technol.* 43:85-95.
- Safina G, Van Lier M, Danielsson B (2008). Flow-injection assay of the pathogenic bacteria using lectin-based quartz crystal microbalance biosensor. *Talanta* 77:468-472.
- Schmidt DD, Kessler A, Kessler D, Schmidt S, Lim M, Gase K, Baldwin IT (2004). *Solanum nigrum*: a model ecological expression system and its tools. *Mol. Ecol.* 13:981-995.
- Sharon N, Lis H (1990). Legume lectins--a large family of homologous proteins. *FASEB J.* 4:3198-3208.
- Swanson MD, Winter HC, Goldstein IJ, Markovitz DM (2010). A lectin isolated from bananas is a potent inhibitor of HIV replication. *J. Biol. Chem.* 285:8646.
- Van Damme EJM, Lannoo N, Peumans WJ (2008). Plant lectins. *Adv. Bot. Res.* 48:107-209.
- Van Damme EJM, Peumans WJ, Barre A, Rougé P (1998). Plant lectins: a composite of several distinct families of structurally and evolutionary related proteins with diverse biological roles. *Critical Reviews in Plant Sciences* 17, 575-692.
- Vandenborre G, Miersch O, Hause B, Smagge G, Wasternack C, Van Damme EJ (2009). *Spodoptera littoralis*-induced lectin expression in tobacco. *Plant Cell Physiol.* 50:1142-1155.
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 3(7): RESEARCH0034.
- Varrot A, Blanchard B, Imberty A (2011). Lectin binding and its structural basis. *Carbohydr. Recogn.* 329-347.
- Vaz AFM, Costa RMPB, Melo AMMA, Oliva MLV, Santana LA, Silva-Lucca RA, Coelho LCBB, Correia MTS (2010). Biocontrol of *Fusarium* species by a novel lectin with low ecotoxicity isolated from *Sebastiania jacobinensis*. *Food Chem.* 119:1507-1513.
- Vega N, Pérez G (2006). Isolation and characterisation of a *Salvia bogotensis* seed lectin specific for the Tn antigen. *Phytochemistry* 67: 347-355.
- Wang W, Peumans WJ, Rouge P, Rossi C, Proost P, Chen J, Van Damme EJ, (2003). Leaves of the Lamiaceae species *Glechoma hederacea* (ground ivy) contain a lectin that is structurally and evolutionary related to the legume lectins. *Plant J.* 33:293-304.
- Wasternack C, Stenzel I, Hause B, Hause G, Kutter C, Maucher H, Neumerkel J, Feussner I, Miersch O (2006). The wound response in tomato--role of jasmonic acid. *J. Plant Physiol.* 163:297-306.
- Yang H, Han L, Sheng T, He Q, Liang J, (2006). Effects of replenishing qi, promoting blood circulation and resolving phlegm on vascular endothelial function and blood coagulation system in senile patients with hyperlipemia. *J. Tradit. Chin. Med.* 26:120-124.
- Zhong GX, Li P, Zeng LJ, Guan J, Li DQ, Li SP, (2009). Chemical characteristics of *Salvia miltiorrhiza* (Danshen) collected from different locations in China. *J. Agric. Food Chem.* 57:6879-6887.

## Full Length Research Paper

# Molecular screening for erythromycin resistance genes in *Streptococcus pyogenes* isolated from Iraqi patients with tonsillo-pharyngites

Hassan N. Ali<sup>1</sup>, Maysaa A. R. Dhahi<sup>2\*</sup> and Abdul Kareem H. Abd<sup>1</sup>

<sup>1</sup>Pharmacology Department, College of Medicine, Al-Nahrain University, Baghdad, Iraq.

<sup>2</sup>Microbiology Department, College of Medicine, Al-Nahrain University, Baghdad, Iraq.

Received 24 April, 2015; Accepted 13 July, 2015

*Streptococcus pyogenes* is the leading cause of uncomplicated bacterial pharyngitis and tonsillitis commonly referred to as strep throat. Erythromycin is administered for patients allergy to penicillin. In this study, 125 throat swab samples were collected from children between 2-12 years old with tonsillo-pharyngitis attended to at the AL-Imammain AL-Kadhimain Medical City-Baghdad-Iraq and Pediatric Caring Hospital-Baghdad-Iraq from February 2014 to February 2015. Only 72 throat swab samples showed bacterial growth. The isolates were identified using Vitek 2 Compact system for Gram-Positive. Antibiotics susceptibility was examined using the BioMérieux Vitek2 compact system AST card. For direct molecular identification of *S. pyogenes*, 16S rRNA and 16S-23S rRNA gene amplification were used. Molecular screening for erythromycin resistance genes *erm(A)*, *erm(B)* and *mef(A)* were done using PCR. The results of identification using Vitek2 GP show that 21 (29.2%) samples were *S. pyogenes*-positive while 51(70.8%) of samples were due to other causes of tonsillo-pharyngitis. The results of molecular identification of *S. pyogenes* strains using 16S rRNA and 16S-23S rRNA amplification showed that only four strains were positive for 16S-23S rRNA, while two strains out of four were also positive for 16S rRNA. According to the results of antibiotic sensitivity, there were seven strains resistant to erythromycin. The results of molecular screening for erythromycin resistant genes showed that all these resistant strains did not contain the resistant genes *erm(A)*, *erm(B)* or *mef(A)*. We conclude that, maybe there was a specific sequence variations in genes used for identification of *S. pyogenes*. Also, resistance to erythromycin could be attributed to causes other than the studied mutations, such as structural modification of erythromycin by phosphorylation, glycosylation or lactone ring cleavage by erythromycin esterase.

**Key words:** *Streptococcus pyogenes*, molecular identification, erythromycin resistance genes.

## INTRODUCTION

*Streptococcus pyogenes* is the leading cause of uncomplicated bacterial pharyngitis and tonsillitis commonly referred to as strep throat. It causes up to 15 to 30% of cases of acute pharyngitis that occurs in children in the age between 5 to 15 years. Other respiratory infections include sinusitis, otitis, and pneumonia. Also, it causes

skin infections and post-streptococcal sequel, rheumatic fever, glomerulonephritis that may follow streptococcal diseases, and occur in 1 to 3% of untreated infections (Cunningham, 2000; Carapetis et al., 2005; Tart et al., 2007). Accurate diagnosis is essential for appropriate antibiotic selection. Penicillin should be a first choice of

antibiotics in acute tonsillitis while macrolides such as erythromycin is reserved for patients allergic to penicillin. Ketolides such as telithromycin have the activity against *S. pyogenes* which is resistance to erythromycin (Ben Zakour et al., 2012; Shulman et al., 2012). The mechanisms of action of erythromycin involve the inhibition of bacterial protein synthesis by binding reversibly to the subunit 50S of the bacterial ribosome, thereby inhibiting translocation of peptidyl-tRNA. The action is bacteriostatic, but can also be bactericidal in high concentrations (Giguere, 2013). Resistance to erythromycin in *S. pyogenes* can be caused by the following main mechanisms: 1) modification of the 23S rRNA by rRNA adenine-N6-methyltransferase encoded by horizontally acquired *erm A* and *erm B* (Jasir et al., 2000; Giovanetti et al., 2003; Albrich et al., 2004; Farrell et al., 2006; Brenciani et al., 2007); 2) active drug efflux via a trans-membrane pump encoded by horizontally acquired *mef*. This mechanism is mediated by a membrane-associated protein that pumps the antibiotic out of the cell, keeping intracellular concentrations low and preventing the binding of antibiotics to the ribosome (Nord et al., 2004; Del Grosso et al., 2011; Giovanetti et al., 2012; Giovanetti et al., 2003) mutations comprising a change in domain V of 23S rRNA as a result of a mutation in all the six copies of *rRNA* gene (Bingen et al., 2002). Additional mechanisms of erythromycin resistance include structural modification of erythromycin by phosphorylation (Davies and Davies, 2010), glycosylation (Hawkey and Jones, 2009), and lactone ring cleavage by erythromycin esterase (Levi and Marshal, 2004).

The 16S rRNA and 23S rRNA are targets for identification of microorganisms at the species, genus or family level. These genes contain both conserved regions and areas of variability sufficient for specific identification of bacteria. The ribosomal intergenic spacer region (ISR), a stretch of DNA that lies between the 16S rRNA and the 23S rRNA subunit genes, proved to be much more variable than the adjacent 16S and 23S ribosomal genes and this region can be used as method of differentiation of many species within genus and as method of identification of certain bacteria (Hassan et al., 2003). In this study, molecular identification of *S. pyogenes* using 16SrRNA and 23SrRNA and screening for erythromycin resistance genes was performed.

## MATERIALS AND METHODS

### Samples collection

One hundred and twenty five throat swab samples were collected from children between 2 to 12 years old with tonsillo-pharyngitis infections attended to by the AL-Imammain AL-Kadhimain Medical

city-Baghdad-Iraq and Pediatric Caring Hospital-Baghdad-Iraq from February 2014 to February 2015. Throat swab samples were taken according to clinical evaluation recommendation of physicians (Vandepitte et al., 2003). Information from patient parent was taken including age, sex, duration of infection, previous treatment and stage of throat infection (acute or chronic). The study protocol was approved by The Ethical Committee of College of Medicine-Al Nahrain University.

### Identification of *S. pyogenes*

Throat swab sample was cultured on blood agar plate that was incubated aerobically with 5 to 10 % CO<sub>2</sub> at 37°C for 18 to 24 h in a candle jar (Vandepitte et al., 2003). The blood agar plates were examined for morphology and cultural characteristic that include appearance of colonies and beta-hemolytic zone around colonies on blood agar plate. For purification, growing beta-hemolytic streptococci was inoculated on sodium azide media, which is consider as a selective agar used for the selective isolation of *S. pyogenes*. Also, catalase test, microscopical examination of Gram stain and Bacitracin sensitivity test were done (Vandepitte et al., 2003). The isolates were identified with Vitek 2 Compact system for Gram-Positive Identification, card 2GP (bioMérieux-France).

### Antibiotics susceptibility assay

Minimal inhibitory concentration (MIC) and antibiotics susceptibility were examined using the BioMérieux Vitek2 compact system AST card (bioMérieux-France) according to manufacturer instructions. It is an automated colorimetric method used for identification of bacteria and for detection susceptibility of bacterial isolates against different type of antibiotics. A suspension of overnight pure culture of *S. pyogenes* was prepared by transferring sufficient quantity of bacterial colonies to 3 ml of sterile saline (0.45%NaCl). The turbidity was adjusted to (0.5-0.63) MacFarland turbidity range and measured using a turbidity meter. Then, the suspension was transferred to the apparatus which contain the card that loaded with 9 type of antibiotics included erythromycin, as indicated in Table 1. Measurement of MIC and sensitivity were done using optical system inside the apparatus and the result that was obtained after 18 h of incubation were computerized analyzed which referred to the MIC and whether this isolate had sensitivity, intermediate sensitivity or resistant to each antibiotic found in the card.

### Identification of *S. pyogenes* strains using PCR

Genomic DNA was extracted from *S. pyogenes* strains using WIZARD Genomic DNA Extraction Kit (Promega, USA) following manufacture instructions. For direct molecular identification of *S. pyogenes*, 16S rRNA and 16S-23S rRNA were used. Two primer sets were used for molecular identification of *S. pyogenes* (Table 2) (Nandi et al., 2008). Briefly, two PCR master mixes (final volume 25 µl per reaction) were prepared, one for each gene as in the following: (final concentration per one réaction): 1XPCR buffer (Promega, USA), 200 µm dNTPs (Promega, USA), 100 pmol of each forward and reverse primers (Alpha, USA) and 1.25 U/reaction of GoTaq DNA polymerase (Promega, USA). Two microliters (equivalent to 100 ng) of DNA was added for each reaction tube, except the no template control tube (NTC). PCR

\*Corresponding author. E-mail: dr\_maysaa@yahoo.com.

**Table 1.** Vitek2 GP susceptibility cards contents.

Antibiotic	Concentrations µg/ml	Calling range	
		≤	≥
Ampicillin	0.5,1,4,8	0.25	16
Benzylpenicillin	0.06,0.12,0.5,2	0.06	8
Cefotaxime	0.25,0.5,1,2	0.12	8
Ceftriaxone	0.12,0.25,1,4	0.12	8
Clindamycin	0.12,0.25,0.5	0.25	1
Erythromycin	1,2,4,16	0.12	8
Levofloxacin	1,2,4,16	0.25	16
Tetracycline	0.12,0.25,1,4	0.25	16
Trimethoprim/ Sulphamethaxazole	8/152,16/304,64/1216	10	320

**Table 2.** Primer sequences and molecular size used in molecular identification of *S. pyogenes*.

Gene	Sequence of forward primer	Sequence of reverse primer	Product size (bp)
16S rRNA (A)	5'AAGAGTTTGATCCTGGCTCAG3'	5'GGTTACCTTGTTACGACTT3'	1500
16-23S rRNA (B)	5'TTGTACACACCGCCCGTCA3'	5'GGTACCTTAGATGTTRCAGTTC3'	800

**Table 3.** Primer sequences and molecular size used in erythromycin resistance genes.

Gene	Sequence of forward primer (5' - 3')	Sequence of reverse primer (5' - 3')	Product size (bp)
<i>erm (A)</i>	AGAAGGTTATAATGAAACAGA	GGCATGACATAAACCTTCAT	260
<i>erm(B)</i>	GAAAAGGTACTIONCAACCAAATA	AGTAACGGTACTTAAATTGTTTAC	640
<i>mef(A)</i>	AGTATCATTAATCACTAGTGC	TTCTTCTGGTACTAAAAGTGG	350

reaction tubes were transferred into thermal cycler (ependrof, Germany) that was programmed as following: 94°C for 2 min followed by 35 cycles of 94°C for 1 min, 49°C for Gene A and 55°C for Gene B for 2 min, 72°C for 2 min. Final extension was done at 72°C for 10 min. The selection of optimum annealing temperature came after multiple optimization experiments. PCR products (10 µl from each) were resolved by 1% agarose gel electrophoresis.

#### Molecular screening for erythromycin-resistant genes in *S. pyogenes*

The sequence of oligonucleotide primers sets used in PCR reactions to amplify resistance genes *erm(A)*, *erm(B)* and *mef(A)* are shown in Table 3. PCR reaction was done according to Morosini et al. (2003). Optimization for annealing temperature was done at 52°C.

#### Statistical analysis

Data were analyzed using SPSS version 16 and Microsoft Office Excel 2007. Nominal data were expressed as number and percent. Fischer Exact test was used for comparison of frequency. P-value less than 0.05 were considered significant.

## RESULTS

### Isolation and identification of *S. pyogenes*

This study was carried out in 125 throat swabs isolated

from throat of children from 2 to 12 years old. Fifty three of total samples were excluded from this study because no bacteria were isolated. The remaining 72 samples were identified using bacteriological test. Also, commercial Vitek2GP identification card was used and the identifications probabilities were ranged from 86 to 99%. The results obtained by using Vitek2 GP identification system showed that 21 (29.2%) samples were *S. pyogenes* positive and 51(70.8%) samples were due to other causes of tonsillo-pharyngitis as shown in Table 4. The results of molecular identification of *S. pyogenes* strains using 16SrRNA and 16S-23SrRNA showed that only four strains were positive for 16S -23SrRNA, while two strains out of four were also positive for 16S rRNA, as seen in Figure 1.

### Distribution of streptococci throat infection in disease phases acute and chronic tonsillopharyngitis


In this study, the number of isolates from acute cases were 5 isolates which represent (23.81%) of total cases while from chronic cases were 16 isolates which represent (76.19%) of total cases.

### Antimicrobial susceptibility patterns of *S. pyogenes*


The antimicrobial susceptibility patterns of *S. pyogenes*

**Table 4.** Type and number of bacterial strains isolated from children with tonsillopharyngitis by using Vitek identification kit.

Throat swab bacteria isolated	Number of strains	Percentage (%)
<i>Streptococcus pyogenes</i>	21	29.2
<i>Streptococcus agalactiae</i>	2	2.8
<i>Streptococcus pneumonia</i>	4	5.6
<i>Streptococcus mitis</i>	2	2.8
<i>Streptococcus parasanguinis</i>	2	2.8
<i>Staphylococcus aureus</i>	41	56.8
Total	72	100



(A)



(B)

**Figure 1.** Agarose gel electrophoresis of amplified products of identification genes of *S. pyogenes*. **(A)** Agarose gel electrophoresis of amplified products of *16-23SrRNA* of *S. pyogenes*. Lane MW, molecular weight ladder of 100 bp. lane 1, 2, 3 to 9: negative results of *16-23S rRNA* (800 bp); lane 10, 11 and 11' (as double): amplified products of *16-23S rRNA* (800 bp); lane NTC, no template control. **(B)** Agarose gel electrophoresis of amplified products of *16S rRNA* of *S. pyogenes*; lane MW, molecular weight ladder of 100 bp; lane 1, 3, 4: amplified products of *16SrDNA* (1500 bp); lane 2, 5 to 10, negative results of *16SrRNA* (1500 bp); lane NTC: no template control.

**Table 5.** The percentage of sensitivity patterns of *S. pyogenes* isolates against different types of antibiotics.

Antibiotic	Sensitive		Resistant		Intermediate	
	Number	%	Number	%	Number	%
Benzyl Penicillin	21	100	0	0	0	0
Ampicillin	21	100	0	0	0	0
Cefotaxime	8	38.09	13	61.90	0	0
Ceftriaxone	8	38.09	13	61.90	0	0
Levofloxacin	20	95.23	0	0	1	4.76
Erythromycin	11	52.38	7	33.33	3	14.28
Clindamycin	15	71.43	6	28.57	0	0
Tetracycline	10	47.62	11	52.38	0	0
TMS	21	100	0	0	0	0

strains against various types of antibiotics according to Vitek 2 system were shown in Table 5.

#### Molecular screening for erythromycin resistant genes in *S. pyogenes*

According to the results of antibiotic sensitivity obtained by using Vitek2 AST system, there were seven strains resistant to erythromycin. The results of molecular screening for erythromycin resistant genes showed that none of these resistant strains have the resistant genes *erm(A)*, *erm(B)* or *mef(A)*.

#### Telithromycin activity against erythromycin resistant strains of *S. pyogenes*

The result of sensitivity test of telithromycin disc against erythromycin-resistant strains of *S. pyogenes* showed that 6 out of 7 strains have full sensitivity to Telithromycin disc with MIC value of  $\leq 0.5$   $\mu\text{g/ml}$  while the remaining resistant strain showed intermediate sensitivity against this antibiotic with MIC value range from 1 to 2  $\mu\text{g/ml}$ .

## DISCUSSION

### Identification of *S. pyogenes*

The important cause of the tonsillitis is bacterial and viral causes and about 30 to 40% of bacterial tonsillitis cases are caused by *S. pyogenes* (Abd Al-Kareem et al., 2004). Result of this study showed that from 72 patients with tonsillo-pharyngitis, 21 strains indicated the presence of *S. pyogenes*, 2 strains of *Streptococcus agalactiae*, 4 strain of *Streptococcus pneumoniae*, 2 strains of *Streptococcus mitis*, 2 strains of *Streptococcus parasanguinis* and 41 strain of *Staphylococcus aureus*. Kurien et al. (2000) and Wessels (2011) showed that the

most common bacterial pathogens in the upper respiratory tract infection were *S. pyogenes* and *S. aureus*. In addition to identification by using Vitek2, *S. pyogenes* was identified using 16S rRNA and 16S-23S rRNA. The result showed that 4 strain out of 21 carried 16S-23S rRNA, 2 out of these 4 strains additionally carried 16S rRNA. The absence of identification genes in the remaining *S. pyogenes* strains may be due to the genetic variations. It was referred to that the absence of intra-species genetic variation at 16S rRNA subunit but documented variation in inter-genic 16S-23S spacer region (Clarridge, 2004; Petti et al., 2005; Nandi et al., 2008; Lal et al., 2011).

In this study, the percentage of *S. pyogenes* that caused chronic tonsillopharyngitis was 76.19%; this result was significantly higher than the results of Afaf et al. (2004) in Egypt who found that (18.5%) of the *S. pyogenes* strains were responsible for chronic tonsillopharyngitis. The low incidence of streptococcal tonsillopharyngitis in present study may be due to the relatively small number of the throat samples collected from patient with tonsillo-pharyngitis.

### Antibiotic susceptibility patterns of the *S. pyogenes* using Vitek2 AST system

In this study, the susceptibility test of *S. pyogenes* strains using Vitek2 AST showed that all *S. pyogenes* strains were susceptible to penicillin group and penicillin remain the drug of choice for treatment of streptococcal pharyngitis, because the circumstances favorable for the development of resistance have not yet occurred, because this antibiotic is out of use in clinical practice in Iraq nowadays and the preference of the newest antibacterial drugs for prescription, as well as inefficient mechanisms for genetic transfer or barriers to DNA uptake and replication and  $\beta$ -Lactamase may not be expressed or may be potentially toxic to *S. pyogenes* (Malhotra-Kumar et al., 2005; Ramalhinho et al., 2012;

Rubio-Lopez et al., 2012). Also, it could be that PBP<sub>s</sub> of *S. pyogenes* contain no lengthy regions of similarity with genes from other streptococci, making it unlikely that the acquisition of penicillin resistance arises by homologous recombination with genes from other species (Ferretti et al., 2001). This study shows that the susceptibility of strains to cefotaxime and ceftriaxone was 38.09% which is due to the extensive and random prescribing of these antibiotics before doing culture and sensitivity test, as well as those antibiotics in Iraq are supplied as over counter medicines in private pharmacies against the regulations. The results obtained by Young et al. (2004) in South Korea, Oliver et al. (2007) in Spain and Huang et al. (2014) in Taiwan, shows that the susceptibility of *S. pyogenes* to cefotaxime and ceftriaxone was 100%.

In patients who are allergic to penicillin, macrolides such erythromycin and lincosamides such as clindamycin are alternative treatment choices (Shulman et al., 2012). In this study, the percentages of resistance of clindamycin and erythromycin for *S. pyogenes* were 28.75 and 33.33%, respectively. Huang et al. (2014) showed that the resistance to clindamycin and erythromycin were 2.1 and 16.4%, respectively. Other studies referred to low percentages of erythromycin resistance such as in America (8.6%), Asia-pacific region (10.9%), Europe (9.7%) and Latin America (2.7%) (Gordon et al., 2002). Shibl (2005) in Saudia Arabia showed that the resistant was only 6.3%, and similar percentages (4 to 10%) have been reported in Germany, UK, Portugal, Greece and Canada. The level of erythromycin resistance among strains was low which may be related to the low consumption of macrolides in these regions, or may be due to the absence of clonal spread of erythromycin-resistant strains (Silva-Costa et al., 2012). The high percentage that is found in the current study could be attributed to high misuse of antibiotic in Iraq.

### Screening for erythromycin resistant gene

Increases in macrolide resistance have been reported and the rapidly growing problem of antibiotic resistant *S. pyogenes* is increasing (Ray et al., 2010). In Iraq, information regarding the screening for erythromycin resistant genes of *S. pyogenes* strains was largely loosing. In this study, there were no strains related to *S. pyogenes* carrying the resistant genes. Bingen et al. (2000) referred that the predominance of a particular resistance genotype among macrolide-resistant strains were *mefA* in Spain (97% of 437 strains), Belgium (84% of 131 strains), Germany (56% of 54 strains) and Canada (92% of 72 strains) and *ermB* in France (55% of 93 strains). Richter et al. (2005) refereed to that of the population of macrolide-resistant *S. pyogenes* strains in the United States comprises similar proportions of strains containing *mefA* (43%) and *ermA* (46%), with a smaller fraction of strains having *ermB* (8.5%) and considerable variation among regions. A study by Dundar et al. (2010)

in Turkey show that of 3 of 11 erythromycin resistant strains of *S. pyogenes* did not have *erm(A)*, *erm(B)*, and *mef(A)* and this may be due to the ribosomal mutations.

### Effect of telithromycin on erythromycin resistant *S. pyogenes*

In this study, 6 out of the 7 erythromycin resistant strains had high sensitivity to telithromycin with MIC value  $\leq 0.5$   $\mu\text{g/ml}$  while the remaining strain show intermediate resistance with MIC value range between 1 to 2  $\mu\text{g/ml}$ . Such results may justify the effectiveness of this antibiotic as alternative of erythromycin in the treatment of streptococcal pharyngitis (Camara et al., 2013). Telithromycin was more active than 14 and 15 membered ring macrolides (azithromycin and clarithromycin) against erythromycin resistant *S. pyogenes* strains (Jalava et al., 2001). Telithromycin show good activity against clinical *S. pyogenes* isolates including erythromycin A-resistant strains harboring the *erm(A)* or *mef(A)* (efflux) genotype.

### Conflict of interests

The author(s) did not declare any conflict of interest.

### REFERENCES

- Abd Al-Kareem FE, Abbas AKH, Hussein MA (2004). Comparative study of the Antibody Responses to *Streptococcus pyogenes* between school Children carriers and patients with Tonsillitis. Iraqi J. Sci. 55:403-410.
- Afaf S, Abdulrahman L, Kholeif A, El-Beltagy YM, Eldesouky AA (2004). Bacteriology of tonsil surface and core in children with chronic tonsillitis and incidence of bacteremia during tonsillectomy. Egypt J. Med. Lab. Sci. 13:1-9.
- Albrich WC, Monnet DL, Harbarth S (2004). Antibiotic selection pressure and resistance in *Streptococcus pneumoniae* and *Streptococcus pyogenes*. Emerg. Infect. Dis. 10:514-517.
- Ben Zakour NL, Venturini C, Beatson SA, Walker MJ (2012). Analysis of a *Streptococcus pyogenes* puerperal sepsis cluster by use of whole-genome sequencing. J. Clin. Microbiol. 50:2224-2228.
- Bingen E, Fitoussi F, Doit C (2000). Resistance to macrolides in *Streptococcus pyogenes* in France in pediatric patients. Antimicrob. Agents Chemother. 44:1453-1457.
- Bingen E, Leclercq R, Fitoussi F, Brahimi N, Malbrun B, Deforche D, Cohen R (2002). Emergence of group A streptococcus strains with different mechanisms of macrolide resistance. Antimicrob. Agents Chemother. 46:1199-1203. [PMC free article] [PubMed].
- Brenciani A, Bacciaglia A, Vecchi M, Vitali LA, Varaldo PE, Giovanetti E (2007). Genetic elements carrying *erm(B)* in *Streptococcus pyogenes* and association with *tet(M)* tetracycline resistance gene. Antimicrob. Agents Chemother. 51:1209-1216.
- Camara M, Dieng A, Boye CSB (2013). Antibiotic Susceptibility of *Streptococcus pyogenes* Isolated from Respiratory Tract Infections in Dakar, Senegal. Microbiol. Insights 6:6 71-675.
- Carapetis JR, Steer AC, Mulholland EK, Weber M (2005). The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5:685-694.
- Clarridge JE (2004). Impact of 16s rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious disease. Clin. Microbiol. Rev. 17:840-862.
- Cunningham MW (2000). Pathogenesis of Group A Streptococcal

- Infections. Clin. Microbiol. Rev.13:470–511.
- Davies J, Davies D(2010).Origin and evolution of antibiotics resistance. Microbiol. Mol. Biol. Rev. 74:417-433.
- Del Grosso MR, Camilli G, Barbabella J, Blackman NDJ, Pantosti A (2011).Genetic resistance elements carrying *mef* subclasses other than *mef(A)* in *Streptococcus pyogenes*. Antimicrob. Agents Chemother. 55:3226-3230.
- Dundar D, Sayan M, Tamer GS(2010). Macrolide and Tetracycline Resistance and emm Type Distribution of *Streptococcus pyogenes* Isolates Recovered from Turkish Patients. Microbial. Drug Res.16: 279-284.
- Farrell DJ, Shackcloth J, Barbadora KA, Green MD (2006). *Streptococcus pyogenes* isolates with high level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutation. Antimicrob. Agents Chemother. 50:817-818.
- Ferretti JJ, McShan WM, Ajdic D, Savic DJ, Savic G, Lyon K, Primeaux C, Sezate S, Suvorov AN, Kenton S, Lai HS, Lin SP, Qian Y, Jia HG, Najjar FZ, Ren Q, McLaughlin R(2001).Complete genome sequence of an M1 strain of *Streptococcus pyogenes*. Proc. Natl. Acad. Sci. U.S.A. 98:4658–4663.
- Giguere S (2013). Antimicrobial drug action and interaction.5<sup>th</sup> edition, John Wiley and Sons Inc.
- Giovanetti E, Brenciani A, Lupidi R, Roberts MC, Varaldo PE(2003). Presence of the *tet(O)* gene in erythromycin- and tetracycline-resistant strains of *Streptococcus pyogenes* and linkage with either the *mef(A)* or the *erm(A)* gene. Antimicrob. Agents Chemother. 47:2844–2849.
- Giovanetti E, Brenciani A, Tiberi E, Bacciaglia A, Varaldo PE(2012). ICESp2905, the *erm(TR)-tet(O)* element of *Streptococcus pyogenes*, is formed by two independent integrative and conjugative elements. Antimicrob. Agents Chemother. 56:591–594.
- Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH (2002). Antimicrobial susceptibility patterns of beta-hemolytic and viridans group *Streptococci*: report from the SENTRY Antimicrobial surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. 43:157-162.
- Hassan AA, Khan IU, Abdulmajood A, Lammler C(2003). Inter- and intraspecies variations of the 16S-23S rDNA intergenic spacer region of various streptococcal species. Syst. Appl. Microbiol. 26:97-103.
- Hawkey PM, Jones AM (2009). The changing epidemiology of resistance. J. Antimicrob. Chemother. 64:3-10.
- Huang CY, Lai JF, Huang IW, Chen PC, Wang HY, Shiau YR, Cheng YW, Hsieh LY, Chang SC, Yang Lauderdale TL(2014). Epidemiology and Molecular Characterization of Macrolide-Resistant *Streptococcus pyogenes* in Taiwan. J. Clin. Microbiol. 52: 508–516.
- Jalava J, Kataja J, Seppala H, Huovien V(2001). *In Vitro* Activities of the Novel Ketolide Telithromycin (HMR 3647) against Erythromycin-Resistant *Streptococcus* Species. Antimicrob. Agents Chemother. 45: 789–793.
- Jasir A, Tanna A, Noorani A, Mirsalehian A, Efstratiou A, Schalen C (2000) .High rate of Tetracycline resistance in *Streptococcus pyogenes* in Iran: an epidemiological study. J. Clin. Microbiol. 75: 2103-2107.
- Kurien M, Stanis A, Job A, Brahamadathan TK(2000). Throat swab in the chronic tonsillitis: How reliable and valid is it? Singapore Med. J. 41: 324 – 326.
- Lal D, Verma M, Lal R (2011). Exploring internal features of 16 s rRNA gene for identification of clinically relevant species of the genus streptococcus. Anal. Clin. Microbiol. Antimicrob.10:28.
- Levi SB, Marshal B (2004). Antibacterial resistance worldwide causes, challenges and responses. Nat. Med.10:122-129.
- Malhotra-Kumar S, Lammens C, Chapelle S, Wijdooghe M, Piessens J, Van Herck K,Goossens H(2005). Macrolide and telithromycin-resistant *Streptococcus pyogenes*, Belgium, 1999-2003. Emerg. Infect. Dis. 11:939-942.
- Morosini MI, Cantón R, Loza E, Campo RD, Almaraz F,Baquero F (2003). *Streptococcus pyogenes* isolates with characterized macrolide resistance mechanisms in Spain: *in vitro* activities of Telithromycin and cethromycin. J. Antimicrob. Chemother. 52: 50–55.
- Nandi S, Ganguly NK, Kumar R, Bakshi DK, Sagar V, Chakraborti A(2008). Genotyping of group A streptococcus by various molecular methods. Indian J. Med. Res.127: 71-77.
- Nord CE, Farrell DJ, Leclercq R(2004). Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections. Microb. Drug Resist.10: 255–63.
- Oliver MA, García-Delafuente C, Cano ME, Pérez-Hernández F, Martínez-Martínez L, Albert S(2007). Rapid decrease in the prevalence of macrolide-resistant group A streptococci due to the appearance of two epidemic clones in Cantabria (Spain). J. Antimicrob. Chemother. 60:450–452.
- Petti CA, Palage CR, Schreckenberger P(2005). The role of 16S rRNA gene sequencing in identification of microorganisms misidentified by conventional methods. J. Clin. Microbiol. 43:6123-6125.
- Ramalhinho I, Ribeirinho M, Vieira I, Cabrita J(2012). Evolution of outpatient antibiotic use in Portugal mainland 2000-2009. Acta Med. Port. 25: 20–28.
- Ray D, Sinha S, Saha S, Karmakar S, Dutta RN, Bhattacharya S(2010). A preliminary sentinel surveillance report on antibiotics resistance trend of *Streptococcus pyogenes* in Kolkata region, India. Al Ameen J. Med. Sci. 3:146-151.
- Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Miller AL, Rice CL, Doern CD, Reid SD, Doern GV(2005). Macrolide-Resistant *Streptococcus pyogenes* in the United States, 2002–2003. Clin. Infect. Dis. 41:599–608.
- Rubio-López V, Valdezate S, Alvarez D, Villalón P, Medina MJ, Salcedo C, Sáez-Nieto JA (2012). Molecular epidemiology, antimicrobial susceptibilities and resistance mechanisms of *Streptococcus pyogenes* isolates resistant to erythromycin and tetracycline in Spain (1994- 2006). BMC Microbiol. 12: 215.
- Shibl AM (2005). Patterns of Macrolide Resistance Determinants among *S. pyogenes* and *S. pneumoniae* Isolates in Saudi Arabia. J. Int. Med. Res. 33:349-355.
- Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, Martin JM, Beneden CV(2012). Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin. Inf. Dis. 55 :e86–102
- Silva-Costa C, Fries A, Ramirez M, Melo-Cristino J (2012). Portuguese Group for the Study of Streptococcal Infections. Differences between macrolide-resistant and -susceptible *Streptococcus pyogenes*: importance of clonal properties in addition to antibiotic consumption. Antimicrob. Agents Chemother. 56:5661–5666.
- Tart AH, Walker MJ, Musser JM (2007). New understanding of the group A *Streptococcus* pathogenesis cycle. Trends Microbiol. 15: 318–325.
- Vandepitte J, Engback K, Piot P, Heuk C(2003). Basic Laboratory Procedure in Clinical Bacteriology. 2nd ed. World Health Organization. 60-64, 103-117.
- Wessels MR(2011). Clinical practice. Streptococcal pharyngitis. N. Engl. J. Med. 364:648-655.
- Young UH, Jang IH, Hwang GY, Lee MK, Yoon KJ, Kim HY (2004). Antimicrobial Susceptibility Patterns and Macrolide Resistance 118 Genes of  $\alpha$ -Hemolytic *Streptococci* in Korea. Antimicrob. Agents Chemother. 48: 2716-2718.



## Full Length Research Paper

# Antifungal, acute toxicity and mutagenicity activity of extracts from *Datura stramonium*, *Jacquinia macrocarpa* and *Krameria erecta* on *Fusarium verticillioides*

M. P. Frías-Escalante, A. Burgos-Hernández, M. Plascencia-Jatomea, M. L. Aldana-Madrid and M. O. Cortez-Rocha\*

Departamento de Investigación y Posgrado en Alimentos, Universidad de Sonora, Mexico.

Received 11 December, 2014; Accepted 13 July, 2015

The effect of *Baccharis glutinosa*, *Jacquinia macrocarpa*, and *Krameria erecta* extracts was investigated on the growth and the spore germination of *Fusarium verticillioides* (ATCC 52539). Brine shrimp (*Artemia salina*) was used to evaluate the potential acute toxicity of the fractions obtained from plant extracts. The butanol fraction of *J. macrocarpa* totally inhibited the radial growth for 144 h and up to 95% after 168 h. The ethyl acetate fraction of *B. glutinosa* caused 100% of radial growth inhibition for 96 h. The ethyl acetate fractions of *B. glutinosa* and *K. erecta* caused the higher inhibitory effect on *F. verticillioides* spore germination, 100 and 95%, respectively. All plant fractions tested at a concentration of 5.0 mg mL<sup>-1</sup> caused 100% brine shrimp lethality after 24 h. The Ames test did not reveal the presence of an evident mutagenic activity.

**Key words:** Antifungal activity, plant extracts, brine shrimp bioassay, mutagenicity assay, *Fusarium verticillioides*.

## INTRODUCTION

The plant species in Mexico are more than 26,000 from which 4,000 are estimated to have medicinal use (Mittermeier and Goetsch, 1992). In addition, some of them have exhibited other properties such as antifungal activity and might be considered natural bioactive substances for the control of post-harvest fungal infections. Plant extracts are generally assumed to be more acceptable and less hazardous than synthetic

compounds and they might represent an alternative anti-fungal approach (Jobling, 2000).

*Baccharis glutinosa* Pers (syn.: *Baccharis salicifolia* (Ruiz & Pav.) Pers) and *Jacquinia macrocarpa* (syn.: *Jacquinia aurantica*), are traditional medicinal plants that belong to the *Asteraceae* and *Theophrastaceae* families, respectively (Barrows, 1967; Moreno-Salazar et al., 2008). Ethnic groups from Northwest Mexico have been

\*Corresponding author. E-mail: mcortez@guayacan.uson.mx.

using *B. glutinosa* for gastrointestinal disorders whereas they have used *J. macrocarpa* to prepare a mustard-colored dye from the fruits and a tea out of the flowers that strengthens the heart (Yetman and Van Devender, 2002). Also, cytotoxic and anti-inflammatory properties have been reported for *B. glutinosa* extracts (Fukuda et al., 2006; Abad et al., 2006; Abad and Bermejo, 2007). These plants are widely distributed from Southwest U.S.A. to central Mexico (Barrows, 1967; Moreno-Salazar et al., 2008). *Jacquinia* is native from West Indies where it is known as *J. aurantica*. DiSalvo (1974) reported that *B. glutinosa* aqueous extract of dried powdered leaves to inhibit dermatophytes *in vitro*. He mentioned that *B. glutinosa* is recommended in the southwestern desert of the United States for the therapy of athlete's foot caused by *Tinea pedis*. In addition, *Datura stramonium* has been reported to have antifungal activity.

Fractions from methanolic extracts of these plants have shown antifungal properties against some phytopathogenic and toxigenic molds such as *Aspergillus flavus*, *Aspergillus parasiticus* and *Fusarium verticillioides* (Buitimea-Cantúa et al., 2013). Those authors reported radial growth inhibition, hyphal diameter and length, and mycotoxin production. Based on the above, the aim of this study was to evaluate the antifungal properties of fractions of extracts obtained from *Krameria erecta*, *Baccharis glutinosa*, and *J. macrocarpa* on *F. verticillioides*, and to evaluate their mutagenic potential and acute toxicity.

## MATERIALS AND METHODS

### Plant materials

*J. macrocarpa* Cav. spp. pungens and *Krameria erecta* Willd ex Schult were collected in the area of Los Arrieros, Sonora (Latitude N 28° 20.538' W 111° 08.911' altitude 280 feet and latitude N 28° 19.526' W 111° 08.828' altitude 227 feet) during August 2010. Aerial parts of *B. glutinosa* Pers. were collected during February 2011 in the riverside of Tecoripa River near the rural community of Tecoripa, Sonora. A voucher sample of each plant was deposited at the Herbarium of the Scientific Research and Technology Department of the University of Sonora (DICTUS) in Hermosillo, Sonora (Mexico) to confirm its identification. The plant specimens were sealed in plastic bags, and transported to the laboratory.

### Preparation of antifungal extracts

Plants were sun dried (35-40°C) for 2 weeks and milled (Pulver 200, U.S.A.) to a particle size of 0.5-1.0 mm. Sixty grams of powdered aerial parts of each plant were extracted with 940 ml of 70% methanol by agitation for 1 h with a wrist action Burrel shaker (Burrel Corporation, Pittsburg, PA), and stored at 25°C for 3 days at darkness. The extracts were filtered first through Whatman filter paper No. 1 and then through micropore glass filter. The methanolic extracts (crude extracts) were evaporated to dryness at 40°C with vacuum in a Yamato rotary evaporator RE 300). Crude extracts were evaluated for antifungal activity. The extracts that showed the highest inhibition activity were evaporated to dryness and subjected to fractionation. Twenty grams of dried extracts were suspended in

1 L of water and sequentially partitioned with hexane, ethyl acetate, and n-butanol (Koketsu et al., 1996) and all were tested for antifungal activity. Plates with potato dextrose agar medium, PDA, (DIFCO, USA) were prepared using 5 mg mL<sup>-1</sup> of each fraction [Ethyl acetate fraction of *B. glutinosa* and *K. erecta* (FAe Bg) and (FAe Ke), respectively and n-butanol fraction of *J. macrocarpa* (FB Jm)]. Petri dishes containing PDA prepared with each of the different solvents used for fractionation were used as controls.

### Antifungal activity assay

A strain of *F. verticillioides* (ATCC 52539) was selected for its high fumonisin production. Fungal strain was activated in PDA and incubated at 25 ± 2°C for 10 days. Spores were harvested by pouring a sterile solution of 0.1% (v/v) Tween 80 into the flask and stirring the suspension with a sterile magnetic bar for 5 min. Spore concentration of the suspension was determined using a Neubauer chamber and adjusted to a final concentration of 1 × 10<sup>5</sup> spores/mL. Petri dishes containing PDA medium prepared with 5 mg mL<sup>-1</sup> of plant extract fractions were centrally point-inoculated with 1 × 10<sup>5</sup> spores/mL and incubated in the darkness at 25°C for 7 days. Two types of controls were prepared, one contained PDA medium plus aliquots of each solvent and the other one containing only PDA media. Colony diameters were measured every 24 h using a caliper and compared to those grown in the control media until the fungal growth in the control reached the plate border. All the measurements were carried out by triplicate. The radial growth inhibition percentage was calculated using the following equation: Radial Inhibition (%) = [(Rc-Ri)/Rc] × 100. Where Rc is the mean value of the colony radius in the control media and Ri is the colony radius value of the colonies grown in PDA amended with the partitioned extracts.


### Germination of spores

Petri dishes containing PDA amended with 5 mg mL<sup>-1</sup> of extract fractions (FAe Bg, FAe Ke, and FB Jm) were inoculated by spreading 3 µl of a spore suspension containing 1 × 10<sup>4</sup> spores/mL and incubated at 25°C using a 12 h light/dark cycle (Precision Low temperature Illuminated Incubator 818, U.S.A.). Two types of controls were prepared, one contained PDA medium plus aliquots of each solvent and the other one contained only PDA media. Samples were taken every 4 h of incubation time and 200 spores were counted at random (germinated and non-germinated) using light microscope. Count of spores was performed until the control reached 100% of spores germinated. The number of germinated spores per plate was determined. A spore was considered germinated when the length of its germinal tube reached one-half of the spore diameter. Each germination experiment was made by triplicate. The inhibition of spore germination was determined using Equation 1, in which Si represents the percentage of germinated spores in the plates treated with the extract fraction, and Sc was the percentage of germinated spores in the control containing each of the solvents (Paul et al., 1993).

$$\text{Inhibition (\%)} = \frac{\%S_c - \%S_t}{\%S_c} \times 100$$

### Brine shrimp bioassay

In order to evaluate the potential acute toxicity of the fractions obtained from plant extracts, brine shrimp larvae assay was used (Jiménez et al., 1997). Dried *Artemia salina* eggs (0.1 g) were



**Figure 1.** Radial growth of *Fusarium verticillioides* in PDA amended with 5 mg mL<sup>-1</sup> of extracts fractions from *Jacquinia macrocarpa* (FB Jm), *Krameria erecta* (FAe Ke), and *Baccharis glutinosa* (FAe Bg).

deposited in 1 L of sterile marine water with aeration and light during 24 h to hatch. Brine shrimp larvae were exposed to 5.0, 0.5, 0.005, and 0.0005 mg mL<sup>-1</sup> of the extract fractions for 24, 48, and 72 h. The number of dead larvae was recorded every 24 h to estimate the percentage of mortality. The assay was carried out by quintuplicate.

### Mutagenicity assay

The mutagenic potential of the fractions obtained from plant extracts was determined according to the procedure described by Maron and Ames (1983) using *Salmonella* tester strains TA98 and TA100, with and without bioactivation (S9). Each was placed on nutrient broth (Difco Nutrient Broth) for reproduction during 12 h at 37°C in a circulation water bath at dark. One-hundred microliters of partitioned plant extracts, FAe Bg, FAe Ke and FB Jm, were deposited in test tubes (5, 0.5, 0.005, 0.0005, 0.00005, and 0.00005 mg mL<sup>-1</sup>). Then, each tube was combined with 2.0 mL of bacteriologic agar (Sigma Chemical Co.) supplemented with histidin and biotin, 100 µL of bacterial culture, and 500 µL of S9 mix. This mixture was poured onto minimal glucose agar Petri dishes and incubated for 48 h at 37°C. For mutagenicity, positive control sodium azide was used (without S9) and aflatoxin B1 (with S9). The number of revertants was counted using a colony counter and compared against the controls. The assay was carried out by triplicate.

A completely randomized design of the radial growth and spore germination was carried out. The JMP 2004 software computed the analysis of variance and the means were compared with the Tukey multiple range tests ( $P < 0.05$ ) (JMP vs. 5.0, SAS Institute Inc., USA).

## RESULTS AND DISCUSSION

The extract fractions exhibited a moderate to high

antifungal activity against *F. verticillioides*. No fungicide effect was observed, only an inhibitory activity was detected in the fungus growth when compared to controls. Controls with solvents and pure PDA control showed the higher radial growth. When inoculated on PDA containing the extracts fractions, the radial growth of the fungi was delayed during the incubation time (Figure 1). The BF Jm totally inhibited the radial growth for 144 h and up to 95% after 168 h (Table 1). On the other hand, the FAe Bg caused 100% of radial growth inhibition for 96 h, after that the inhibitory effect was reduced to 72%. Treatment with FAe Ke also inhibited the radial growth in 100% for 48 h and 65% after 72 h of incubation. These results are in agreements with a previous work (Rosas-Burgos et al., 2009), which reported an inhibition of 67% of *F. verticillioides* radial growth. This result is of relevance for the present study because it confirms that *Baccharis glutinosa* has a fungistatic activity; plant specimens used in the present study were collected in a different year to those used by Rosas-Burgos et al. (2009) and similar results were reached. This might suggest that bioactive compounds are present in *B. glutinosa* independently of the year in which the plant is collected. Nevertheless, a recent study showed that concentration of total phenolic compounds and flavonoids on *B. dentata* showed significant seasonal variation (Sartor et al., 2013). Regarding the chemical constituents found in the genus, coumarins, flavonoids and terpenoids are the most frequently reported (Cifuentes et al., 2002; Simoes-Pires et al., 2005; Wachter et al., 1999). On other hand, Kurdelas et al. (2010) isolated three coumarins from *Baccharis darwinii*. The effect of extracts may be

**Table 1.** Radial growth inhibition (%) of *Fusarium verticillioides* in PDA amended with 5 mg mL<sup>-1</sup> of extracts fractions from *Jacquinia macrocarpa* (FB *Jm*), *Krameria erecta* (FAe *Ke*), and *Baccharis glutinosa* (FAe *Bg*).

Incubation time (h)	FB <i>Jm</i>	FAe <i>Ke</i>	Fae <i>Bg</i>
48	100 ± 0.0	100 ± 0.0	100 ± 0.0
72	100 ± 0.0	65 ± 0.0	100 ± 0.0
96	100 ± 0.0	74 ± 0.0	100 ± 0.0
120	100 ± 0.0	81 ± 0.0	81 ± 0.0
144	100 ± 0.0	84 ± 0.0	71 ± 5.1
168	95 ± 8.2	85 ± 1.4	72 ± 3.6

FB *Jm* = n-Butanol fraction of *J. macrocarpa*; FAe *Ke* = ethyl acetate fraction of *K. erecta*; FAe *Bg* = ethyl acetate fraction of *B. glutinosa*.

due to their chemical composition and probably to the membrane composition of the fungi. *B. dracunculifolia* DC, a native plant of South America, is one of the most studied of this genus and baccharin (3-prenyl-4-(dihydrocinnamoyloxy) cinnamic acid) is the chemical compound isolated from its aerial parts. Tabti et al. (2014) mentioned that terpene hydrocarbons and phenolic compounds affects the fungi development. Information on the mechanism(s) of action by these type of compounds in *Baccharis* is not available. Velluti et al. (2005) mentioned that other authors have attributed it not only to the presence of terpenes, phenolic compounds, and other components, but also to the chemical structure, such as the presence of hydroxyl groups in their phenolic compounds.

Also, the values of radial extension rate, determined from the slope of the radial growth versus time during the linear growth phase, were reduced (Table 2). The lower value corresponds to the treatment with FB *Jm* which caused 100% of inhibition. Result indicate that spores inoculated on control treatments began to germinate after 4 h and reached the 100% of germination at 14 h. Spores inoculated on media containing FAe *Bg* and FAe *Ke* caused 100 and 95% germination, respectively at 14 h. On the other hand, spores cultivated in the presence of FB *Jm* were poorly affected.

The fractions FAe *Bg* and FAe *Ke* caused higher inhibitory effect on *F. verticillioides* spore germination, 100 and 95%, respectively (Figure 2). FB *Jm* exerted the lowest effect on spore germination inhibiting only 19.0% and allowed the higher germination velocity compared to the other plant fractions (Figure 2). The first morphological change in spore germination is called swelling in which the diameter of the spore increases. It involves water uptake and a decrease in the microviscosity of the cytoplasm. Also, molecules are directed to the cell cortex to enable addition of new plasma membrane and cell wall (Bartnicki-Garcia and Lippman, 1977; Momany, 2002). At later stages of development, the growth speed of the germ tube increases and the

**Table 2.** *Fusarium verticillioides* spore germination rate on PDA with and without the evaluated extracts fraction (5 mg mL<sup>-1</sup>).


Treatment	Spore germination rate (% EG h <sup>-1</sup> )	Radial extension rate (cm h <sup>-1</sup> )
FAe <i>Bg</i>	0.000	0.0113
FAe <i>Ke</i>	0.354	0.0125
FB <i>Jm</i>	1.438	0.0003
cPDAMeOH	11.406	0.0129
cPDA	11.750	0.0185

FAe *Bg* = *Baccharis glutinosa* ethyl acetate fraction; FAe *Ke* = *Krameria erecta* ethyl acetate fraction; FB *Jm* = *Jacquinia macrocarpa* n-butanol fraction; cPDAMeOH = PDA plus methanol control; cPDA = Control of PDA; EG h<sup>-1</sup> = Germinated spores.

functional organization of the hyphal tip area acquires its full potential. The structure of the fungal cell wall is unique to the fungi and it is composed of chitin, glucans, mannans and glycoproteins (Bowman and Free, 2006). Damage on the fungal cell wall produces morphological alterations, inhibition of fungal growth or apoptotic cell death (Escalante et al., 2008; Alonso et al., 2010; Khan and Nasreen, 2010), which are presumably the result of alterations caused to the components of the cell wall, β-glucan and chitin. Recent research has shown that extracts from *B. glutinosa* and *J. macrocarpa* have chitinase activity against polymeric extracts from *A. flavus* and *F. verticillioides* (Buitimea-Cantúa et al., 2013), which helps to explain our findings.

Table 3 shows the data obtained from the negative control of *A. salina* suspended in marine water. *A. salina* exposed to sodium azide (5.0 and 0.5 mg mL<sup>-1</sup>, positive control) reached 100% mortality after 24 h. All plant fractions tested at a concentration of 5.0 mg mL<sup>-1</sup> caused 100% brine shrimp lethality after 24 h. The extract fraction from *J. macrocarpa* (BF *Jm*) showed similar toxicity effects than sodium azide after 24 h when *A. salina* was either exposed to 5.0 or 0.5 mg mL<sup>-1</sup>. However, when BF *Jm* concentration decreased, the brine shrimp mortality also diminished. This plant extract fraction caused the lowest mortality from the three plant extracts evaluated. The other two extracts showed similar mortality at all of the concentrations evaluated. Our results suggest the presence of toxic compounds in each of the plant extracts, which are able to physiologically affect *A. salina*.

The positive mutagenicity controls, sodium azide and aflatoxin B1, tested in *Salmonella* Thyphimurim strains TA 98 and TA 100, are presented in Table 4. We observed that they were sensitive in this experiment and reproducible results could be achieved. Plant extracts did not induced any mutagenic effect on both *Salmonella* tester strains (Table 5). Mutagenicity exerted by extracts was considered negative since the number of revertant



**Figure 2.** Radial growth of *Fusarium verticillioides* in PDA amended with 5 mg mL<sup>-1</sup> of extracts fractions from *Jacquinia macrocarpa* (FB Jm), *Krameria erecta* (FAe Ke), and *Baccharis glutinosa* (FAe Bg).

**Table 3.** Mortality of *Artemia salina* when exposed to different treatments

Treatment (mg mL <sup>-1</sup> )	Exposition time (h)		
	24	48	72
Marine water with sodium azide	1.67 ± 1.7 <sup>a</sup>	4.71 ± 4.7 <sup>a</sup>	84 ± 5 <sup>a</sup>
0.005	4 ± 4 <sup>a</sup>	36 ± 12 <sup>b</sup>	84 ± 2 <sup>a</sup>
0.05	24 ± 6 <sup>b</sup>	58 ± 13 <sup>c</sup>	93 ± 5 <sup>b</sup>
0.5	100 ± 0 <sup>c</sup>	100 ± 0 <sup>f</sup>	100 ± 0 <sup>c</sup>
5.0	100 ± 0 <sup>c</sup>	100 ± 0 <sup>f</sup>	100 ± 0 <sup>c</sup>
<b>FB Jmb</b>			
0.005	26 ± 4 <sup>b</sup>	55.6 ± 12 <sup>bc</sup>	92.71 ± 3 <sup>b</sup>
0.05	55 ± 10 <sup>c</sup>	70 ± 10 <sup>d</sup>	97 ± 2 <sup>b</sup>
0.5	99 ± 0.8 <sup>e</sup>	100 ± 0 <sup>f</sup>	100 ± 0 <sup>c</sup>
5.0	100 ± 0 <sup>e</sup>	100 ± 0 <sup>f</sup>	100 ± 0 <sup>c</sup>
<b>FAe Ke</b>			
0.005	54.7 ± 10 <sup>c</sup>	86 ± 5 <sup>e</sup>	97 ± 2 <sup>b</sup>
0.05	88 ± 8.5 <sup>d</sup>	96 ± 4 <sup>f</sup>	100 ± 0 <sup>c</sup>
0.5	81.1 ± 6.8 <sup>d</sup>	100 ± 0 <sup>f</sup>	100 ± 0 <sup>c</sup>
5.0	100 ± 0 <sup>e</sup>	100 ± 0 <sup>f</sup>	100 ± 0
<b>FAe Bg</b>			
0.005	49.1 ± 14 <sup>c</sup>	89 ± 4.6 <sup>e</sup>	99.2 ± 0.8 <sup>c</sup>
0.05	60.2 ± 12 <sup>c</sup>	95.5 ± 2 <sup>ef</sup>	100 ± 0 <sup>c</sup>
0.5	87.5 ± 5 <sup>d</sup>	92.8 ± 3 <sup>f</sup>	100 ± 0 <sup>c</sup>
5.0	100 ± 0 <sup>e</sup>	100 ± 0 <sup>f</sup>	100 ± 0 <sup>c</sup>

FB Jm = *Jacquinia macrocarpa* n-butanol fraction; FAe Ke = *Krameria erecta* ethyl acetate fraction; FAe Bg = *Baccharis glutinosa* ethyl acetate fraction.

**Table 4.** *Salmonella* test strains TA98 and TA100, with and without bioactivation (S9) exposed to different concentrations of mutagenicity positive controls.

Concentration (mg mL <sup>-1</sup> )	TA 98			TA 100		
	RI	RE	RM	RI	RE	RM
<b>Sodium azide without S9</b>						
0.015	922 ± 65 <sup>b</sup>	26	35	2140 ± 111.4	224	10
0.15	1147 ± 117 <sup>c</sup>	26	44	2388 ± 67.7	224	11
1.5	2053 ± 88 <sup>d</sup>	26	79	3474 ± 317.0	224	15
15	253 ± 42 <sup>a</sup>	26	10	1626 ± 213.0	224	7
<b>Aflatoxin B1 with S9</b>						
5	41.0 ± 7 <sup>a</sup>	26	1.58	236 ± 12.5	224	1.16
50	42.0 ± 3 <sup>a</sup>	26	1.63	278 ± 15.6	224	1.36
500	932.0 ± 46 <sup>c</sup>	26	35.86	2867 ± 415.0	224	14.1
5000	205.0 ± 9 <sup>b</sup>	26	7.88	329 ± 66.3	224	1.6

RE = Spontaneous revertants; RI = induced revertants; RM = mutagenicity ratio.

**Table 5.** Antimutagenic potential of the plant extracts fractions. Both *Salmonella* test strains TA98 and TA100, with and without bioactivation (S9), were exposed to different concentrations of the extracts fractions.

Concentration (mg mL <sup>-1</sup> )	Bg FAe TA 100	Bg FAe TA 98	Jm FB TA 100	Jm FB TA 98	Ke FAe TA 100	Ke FAe TA 98
<b>With S9</b>						
0	231.5 ± 10.6	34.5 ± 12.0	162.5 ± 48.8	47.5 ± 9.2	187 ± 83.4	45.5 ± 12.0
0.00005	201.5 ± 17.7	33 ± 4.2	229 ± 82.3	49 ± 11.3	272.5 ± 13.4	36 ± 5.7
0.0005	217 ± 42.4	44.5 ± 12.0	221 ± 77.8	53 ± 8.5	276 ± 9.9	36 ± 0
0.005	271.5 ± 10.6	40 ± 4.2	258.5 ± 51.6	43 ± 4.2	261.5 ± 37.5	34.5 ± 4.9
0.05	245.5 ± 7.8	36 ± 4.2	257.5 ± 21.9	34 ± 1.4	271.5 ± 50.2	30.5 ± 6.4
0.5	241.5 ± 24.7	38 ± 1.4	277 ± 15.6	38.5 ± 7.8	295 ± 46.7	53 ± 29.7
5	191 ± 48.1	41.5 ± 2.1	278.5 ± 16.3	42 ± 21.2	210 ± 53.7	34 ± 41.0
<b>Without S9</b>						
0	231.5 ± 10.6	34.5 ± 12.0	162.5 ± 48.8	47.5 ± 9.2	187 ± 83.4	45.5 ± 1.0
0.00005	212 ± 4.2	35 ± 14.1	242 ± 15.6	43.5 ± 10.6	225 ± 2.8	40 ± 0
0.0005	214 ± 5.7	32 ± 5.6	248 ± 26.8	37 ± 1.4	256 ± 19.8	39 ± 9.8
0.005	225.5 ± 0.7	28 ± 0	237.5 ± 16.7	41 ± 1.4	194 ± 39.6	36 ± 9.8
0.05	250.5 ± 36.6	26 ± 2.8	240.5 ± 0.7	38 ± 4.24	204 ± 42.4	42 ± 19.8
0.5	231.5 ± 3.5	26.5 ± 0.7	242 ± 1.4	42 ± 0	229.5 ± 24.7	44.5 ± 9.2
5	192 ± 11.3	28.5 ± 3.5	266 ± 7.1	33 ± 1.4	230.5 ± 24.7	56 ± 12.7

All values represent mean of triplicate determination ± standard deviation.

per plate observed did not double the number of spontaneous revertants. Similar findings have been reported (Nogueira et al., 2011); they found that fractions from *Baccharis trimera*, evaluated *in vivo* and *in vitro*, were not mutagenic. Also, other authors reported no genotoxic activity of *Baccharis incarum* on *Drosophila melanogaster* (Berzain and Rodrigo, 2006). These findings suggest that the genus *Baccharis* might not be of potential toxicity to superior animal organisms; however, further investigation should be performed for a full toxicity assessment.

This study indicates that the plant extracts had anti-fungal activity on *F. verticillioides* and can be exploited in the future to reduce fungal spread. They delayed radial growth during the incubation time. Ethyl acetate fractions of *B. glutinosa* and *K. erecta* caused the higher inhibitory effect on *F. verticillioides* spore germination, 100 and 95%, respectively. Suppression on spore production could be the major contribution to limit the pathogen spread. Plant fractions tested at 5.0 mg mL<sup>-1</sup> caused 100% brine shrimp lethality after 24 h and the Ames test did not reveal mutagenic activity.

## Conflict of interests

The author(s) did not declare any conflict of interest.

## ACKNOWLEDGMENTS

The authors are grateful to CONACYT (Mexican Council for Science and Technology) for the grant 58249.

## REFERENCES

- Abad MJ, Bermejo P (2007). *Baccharis* (Compositae): A review update. *Arkivoc.* 7:76-79.
- Abad MJ, Bessa AL, Ballarin B, Aragon O, Gonzalez E, Bermejo P (2006). Anti-inflammatory activity of four Bolivian *Baccharis* species (Compositae). *J. Ethnopharmacol.* 103(3):338-244.
- Alonso F, Cirigliano AM, Cabrera GM, Ramírez JM (2010). Synthesis and preliminary biological screening of sterol analogues as new antifungal agents against plant pathogens. *Steroids* 75(10): 659-664.
- Barrows DP (1967). Ethno-botany of the Coahuilla Indians of Southern California. Banning, CA: Malki Museum Press. p. 78.
- Bartnicki-Garcia S, Lippman E (1977). Polarization of cell wall synthesis during spore germination of *Mucor rouxi*. *Exp. Mycol.* 1(3): 230-240.
- Berzaín C, Rodrigo G (2006). Evaluación genotoxicológica del extracto etéreo de *Baccharis incarum*. *BIOFARBO* 14:11-15. <http://www.ops.org.bo/textocompleto/rmbiofa20061402.pdf>
- Bowman SM, Free SJ (2006). The structure and synthesis of the fungal cell wall. *Bioessays* 28(8):799-808.
- Buitimea-Cantúa G, Rosas-Burgos E, Cinco-Moroyoqui F, Burgos-Hernández A, Plascencia-Jatomea M, Cortez-Rocha M, Gálvez-Ruiz J (2013). *In vitro* effect of antifungal fractions from the plants *Baccharis glutinosa* and *Jacquinia macrocarpa* on chitin and  $\beta$ -1,3-glucan hydrolysis of maize phytopathogenic fungi and on the fungal  $\beta$ -1,3-glucanase and chitinase activities. *J. Food Saf.* 33(4):526-535.
- Cifuentes DA, Borkowski EJ, Sosa ME, Gianello JC, Giordano OS, Tonn CE (2002). Clerodane diterpenes from *Baccharis sagittalis*: insect antifeedant activity. *Phytochemistry* 61(8): 899-905.
- DiSalvo AF (1974). Antifungal properties of a plant extract I. Source and spectrum of antimicrobial activity. *Mycophatol. Mycol. Appl.* 54(2): 215-219.
- Escalante A, Gattuso M, Pérez P, Zacchino S (2008). Evidence for the mechanism of action of the antifungal phytolaccoside B isolated from *Phytolacca tetramera* Hauman. *J. Nat. Prod.* 71(10):1720-1725.
- Fukuda M, Ohkoshi E, Makino M, Fujimoto Y (2006). Studies on the constituents of the leaves of *Baccharis dracunculifolia* (Asteraceae) and their cytotoxic activity. *Chem. Pharm. Bull.* 54(10): 1465-1468.
- Jiménez M, Huerta T, Mateo R (1997). Mycotoxin production by *Fusarium* species isolated from bananas. *Appl. Environ. Microbiol.* 63(2):364-369.
- Jobling J (2000). Essential oils: A new idea for postharvest disease control. *Good Fruit and Vegetables Magazine* 11: 50.
- Khan ZS, Nasreen S (2010). Phytochemical analysis, antifungal activity and mode of action of methanol extracts from plants against pathogens. *J. Agric. Technol.* 6(4):793-805.
- Koketsu M, Kim M, Yamamoto T (1996). Antifungal activity against food-borne fungi of *Aspidistra eliator* Blume. *J. Agric. Food Chem.* 44(1):301-303.
- Kurdelas RR, Lima B, Tapia A, Egly Feresin G, Gonzalez Sierra M, Rodríguez MV, Zacchino S, Enriz RD, Freile ML (2010). Antifungal activity of extracts and prenylated coumarins isolated from *Baccharis darwinii* Hook & Arn. (Asteraceae). *Molecules* 15(7):4898-4907.
- Maron D, Ames B (1983). Revised methods for the *Salmonella* mutagenicity test. *Mutat. Res.* 113(3-4):173-215.
- Mittermeier R, Goettsch C (1992). La importancia de la diversidad biológica de México. In: *México ante los Retos de la Biodiversidad*. Edited by Comisión Nacional para la Biodiversidad. México, D.F. pp. 57-62.
- Momany M (2002). Polarity in filamentous fungi: Establishment, maintenance and new axes. *Curr. Opin. Microbiol.* 5(6): 580-585.
- Moreno-Salazar SF, Robles-Zepeda RE, Johnson DE (2008). Plant folk medicines for gastrointestinal disorders among the main tribes of Sonora, Mexico. *Fitoterapia* 79(2):132-141.
- Nogueira NPA, Reis PA, Laranja GAT, Pinto AC, Aiub CAF, Felzenszwalb I, Paes MC, Bastos FF, Bastos VLF, Sabino KCC, Coelho MGP (2011). *In vitro* and *in vivo* toxicological evaluation of extract and fractions from *Baccharis trimera* with anti-inflammatory activity. *J. Ethnopharmacol.* 138(2):513-522.
- Paul GC, Kent CA, Thomas CR (1993). Viability testing and characterization of germination of fungal spores by automatic image analysis. *Biotechnol. Bioeng.* 42(1):11-23.
- Rosas-Burgos EC, Cortez-Rocha MO, Cinco-Moroyoqui FJ, Robles-Zepeda RE, López-Cervantes J, Sánchez-Machado DI, Lares-Villa F (2009). Antifungal activity *in vitro* of *Baccharis glutinosa* and *Ambrosia confertiflora* extracts on *Aspergillus flavus*, *Aspergillus parasiticus* and *Fusarium verticillioides*. *World J. Microb. Biotechnol.* 25(12): 2257-2261.
- Sartor T, Xavier MA, Mondin CA, dos Santos MA, Cassel A, Astarita LV, Satarém ER (2013). Seasonal changes in phenolic compounds and in the biological activities of *Baccharis dentata* (Vell) G.M. Barroso. *Ind. Crop Prod.* 51: 355-359.
- Simoës-Pires CA, Queiroz EF, Henriques AT, Hostettmann K (2005). Isolation and on-line identification of antioxidant compounds from three *Baccharis* species by HPLC-UV-MS/MS with post-column derivatization. *Phytochem. Anal.* 16(5):307-314.
- Tabti L, Dib MEA, Gaouar N, Samira B, Tabti B (2014). Antioxidant and antifungal activity of extracts of the aerial parts of *Thymus capitatus* (L.) Hoffmanns against four phytopathogenic fungi of *Citrus sinensis*. *Jundishapur J. Nat Pharm. Prod.* 9(1):49-54.
- Velluti A, Sanchis V, Ramos AJ, Egido J, Marin S (2005). Inhibitory effect of cinnamon, clove, lemongrass, oregano and palmarose essential oils on growth and fumonisin B1 production by *Fusarium proliferatum* in maize grain. *Int. J. Food Microbiol.* 89(2-3):145-154.
- Wachter GA, Montenegro G, Timmermann B (1999). Diterpenoids from *Baccharis pingraea*. *J. Nat. Prod.* 62(2):307-308.
- Yetman D, Van Devender T (2002). Mayo ethnobotany: Land, history, and traditional knowledge in Northwest Mexico. University of California Press, 372 p.

Full Length Research Paper

## Connecting DNA origami structures using the biotin-streptavidin specific binding

Amoako George<sup>1, 2</sup>, Ming Zhou<sup>2\*</sup>, Rian Ye<sup>2</sup>, Mensah-Amoah Patrick<sup>1</sup>, Twum Anthony<sup>1</sup> and Sam Frederick<sup>1</sup>

<sup>1</sup>Department of Physics, University of Cape Coast, Cape Coast, Ghana.

<sup>2</sup>The State Key Laboratory of Tribology, Tsinghua University, Beijing 100084, P. R. China.

Received 4 May, 2015; Accepted 6 July, 2015

**This work made use of the strong interaction between biotin and streptavidin to connect designed DNA origami structures. The caDNAno software was used to design a 6 layer 3D origami cross-like structure. Selected DNA strands at the engineered attachment sites on the DNA origami structure were biotinylated. After folding of the origami structures, the biotinylated strands stick out of the attachment sites. Purified samples of origami structures were then mixed with streptavidin and the mixture purified. After characterization, we see that attachment only occurs at the biotinylated sites. Agarose gel electrophoresis, UV-vis spectroscopy and TEM were used to characterize the structure.**

**Key words:** DNA origami, interaction, biotin-streptavidin, nanomaterials, TEM.

### INTRODUCTION

The specific binding of bases is exploited to self-assemble DNA which gives a large amount of control over nanoscale devices assembly. Seeman (1982, 2003) laid down the theoretical model that allowed the use of DNA as a building material for the construction of devices at the nanoscale. DNA has the capacity to be programmed for self-assembly and has also a high stability making it possible to be used in device construction. There are a large number of materials ranging from metals, semiconductors to biological materials that can chemically be attached to DNA. Researchers have used DNA to construct a large number

of composite structures (Chen and Seeman, 1991; Ekani-Nkodo et al., 2004; Fu and Seeman, 1993; Hou et al., 2005; Li et al., 1996; Liu et al., 1999; Winfree et al., 1998). The search continued to build miniaturized structures to design advanced materials with high performance. Rothmund (Rothmund, 2006) came out with the versatile, robust and significant DNA origami method which could be used to construct both 2-D and 3-D structures. The DNA origami method encompasses the folding of a long single-stranded scaffold DNA by shorter single-stranded staple DNA sequences. The mixture is then heated and annealed at room temperature for

\*Corresponding author: E-mail: [zhouming@tsinghua.edu.cn](mailto:zhouming@tsinghua.edu.cn). Tel: 00861062783968.

Author(s) agree that this article remains permanently open access under the terms of the [Creative Commons Attribution License 4.0 International License](https://creativecommons.org/licenses/by/4.0/)

**Abbreviations:** EDTA, Ethylenediaminetetraacetic acid; TEM, Transmission electron microscopy.



several hours or days depending on whether single- or multi-layered structures are involved (Douglas et al., 2009a; Douglas et al., 2009b).

Rothemund was the first to demonstrate the functionalization of DNA origami surfaces (Rothemund, 2006). Since then other researchers have used varying arrays of nanomaterials to functionalize origami surfaces. This is made possible by the use of sticky ends which protrude on the surface. Nanomaterials which are functionalized with complementary sequences are then made to hybridize with these sticky ends. In so doing they attach themselves on the surface. The covalent bond between gold and sulfur is employed in the case of gold. Several groups have made use of this approach (Amoako et al., 2013; Ding et al., 2010; Maune et al., 2010, Pilo-Pais et al., 2011; Shen et al., 2012) to functionalize origami structures. Several groups (Jungmann et al., 2011; Lavella et al., 2012) have made use of the strong biotin-streptavidin interaction to functionalize DNA and DNA origami structures.

Selected staples are modified and extended with biotin making it possible for streptavidin binding with the DNA strand or DNA origami structures. Li et al. (2004) used this interaction to control the templating of two forms of triple crossover molecules through self-assembly. Lonnais et al. (2008) also used the interaction to conjugate DNA and carbon nanotubes. Eskelinen (Eskelinen et al., 2011) and fellow workers have also used the biotin-streptavidin interaction to assemble carbon nanotubes on DNA origami. In order to reconfigure DNA origami pliers, Kuzuya (Kuzuya et al., 2011) and colleagues used the strong binding biotin-streptavidin interaction.

All these researchers made use of the biotin-streptavidin interaction to functionalize the DNA strand or DNA origami structures. In this work, we demonstrate the use of this interaction to connect two or more DNA origami structures. The square lattice caDNAo (Ke et al., 2009) software was used to design a six layered 3D origami cross-like structure. The connecting sites with DNA strands extended with biotin were designed at the two ends of the long axis of the cross-like origami structures. By means of streptavidin addition to the DNA origami solution, the origami structures are extended.

## MATERIALS AND METHODS

### Chemicals and supplies

Ethylenediaminetetraacetic acid (EDTA), ultrapure purified DNA oligonucleotides, streptavidin and DNA oligonucleotides extended with biotin were purchased from Sangon Biotech (Shanghai, China) Co. Ltd. Tris(hydroxymethyl) aminomethane (Tris), Agarose M, and magnesium acetate tetrahydrate ((CH<sub>3</sub>COO)<sub>2</sub>Mg·4H<sub>2</sub>O) were obtained from Bio Basic Inc (Markham, Canada). NA-red, and 6X loading buffer were bought from Beyotime Institute of Biotechnology (Haimen, China). Wide range DNA marker was purchased from Takara Biotechnology (Dalian, China) Co. Ltd. The single-stranded viral genomic DNA M13mp18 used in the experiments was purchased

from New England Biolabs (Ipswich, UK). We purchased boric acid (H<sub>3</sub>BO<sub>3</sub>), magnesium chloride (MgCl<sub>2</sub>), and acetic acid (C<sub>2</sub>H<sub>4</sub>O<sub>2</sub>) from Sinopharm Chemical Reagent (Shanghai, China) Co. Ltd. Freeze 'N' Squeeze DNA gel-extraction spin columns were bought from Bio-Rad Laboratories Inc. (Hercules, USA). Carbon copper grids and mica were purchased from Beijing Zhongjingkeyi Technology Co. (China) Ltd. and finally uranyl acetate (UO<sub>2</sub>(CH<sub>3</sub>COO)<sub>2</sub>·2H<sub>2</sub>O) was purchased from Structure Probe, Inc. (Beijing, China).

### Folding and purification of DNA origami cross-like structures


Our sample was prepared based on the procedures outlined in (Castro et al., 2011) with slight changes to the annealing process by combining 10 nM scaffold (M13mp18), 100 nM of each of the 178 staple oligonucleotides which were used without further purification, buffer and salts including 5 mM Tris, 1 mM EDTA (PH 7.9 at 20°C), and a magnesium screen covering 7 different concentrations from 12 mM at 2 mM intervals to 24 mM MgCl<sub>2</sub>. Folding was carried out by rapid heat denaturation to 65°C followed by slow cooling from 65 to 60°C over 50 min, then 60 to 24°C over 72 h. We performed electrophoresis on samples using 2% Agarose gel (0.5X Tris/Borate/EDTA (TBE), 11 mM MgCl<sub>2</sub>, 10 μL NA-red) at 70 V for 3.5 h in an ice-water bath. Discrete bands were visualized with UV trans-illuminator (Peiqing JS-680B). The desired bands were physically excised, crunched and filtered through a Freeze 'N' Squeeze spin column at 4°C for 10 min at 16000 xg.

### TEM imaging


Transmission electron micrographs were obtained with a HITACHI H-7650B TEM (Hitachi, Japan). A 3 μL DNA origami sample solution was deposited onto the carbon-coated side of the TEM grid and allowed to adsorb for about 5 min. The sample-side of the grid was then immersed in a 2% uranyl acetate stain-solution droplet and incubated for 40 s. Excess liquid was dabbed off with the edge of a filter paper, and the grid allowed to dry completely. Images were taken at 80.0 kV accelerating voltage.

## RESULTS AND DISCUSSION

The square lattice based caDNAo software was used to design a 3D DNA origami cross-like structure (since the structure resembled a cross). Our design consisted of an overall 72-helix bundle which was all used to form the structure. The design consists of six layers having a total height of 12 nm. The width of the design consists of 12 helices thus the design is 24 nm wide. We estimated the length of the design from caDNAo to be approximately 38 nm. Therefore, the cross-like origami structure has approximate dimensions of 12 × 24 × 38 nm. Figure 1a shows a model depiction of the cross-like structure as designed. Figure 1b shows the folding scheme of the DNA origami cross-like structure. To prevent base stacking of the structures, we removed all the end sequences. We prepared a magnesium screen covering seven different concentrations from 12 mM at 2 mM intervals to 24 mM MgCl<sub>2</sub>. The quality of folding was assessed by running a 2% agarose gel electrophoresis of the folded structures. The origami solutions containing the respective MgCl<sub>2</sub> salts are shown in Figure 2a. Lanes



**Figure 1.** a. Model depiction of the 3D DNA origami cross-like structure. The scaffold strand is shown in light blue color, while the other colors represent the staple strands. b. Folding scheme of the DNA origami cross-like structure.




**Figure 2.** 2% agarose gel electrophoresis of the samples in the magnesium screen. i) Lane 1 contains M13mp18, ii) lanes 2 to 8 contained, respectively solutions from 12 to 24 mM Magnesium salts. The leading bands of lanes 2 to 8 were excised and purified for our objects and under the bands are excess staples. (b) TEM image of the 3D DNA origami cross-like structure with the scale bar indicated. Scale 20 nm.

2 to 8 in Figure 2a contained respectively 12 mM<sup>-24</sup> mM MgCl<sub>2</sub>. The band that contained the 12 mM salts was the fastest migrating and also the clearest. We physically excised this band and purified the structures via centrifugation using freeze 'n' squeeze DNA gel extraction spin columns. We performed transmission electron microscopy (TEM) on the purified structures and realized that the structures folded in 12 mM MgCl<sub>2</sub> yielded the best results. The TEM image of a single cross-like structure is shown in Figure 2b. In the figure, we see the clearly formed cross-like structure. Since the size of the single structure was very small, it was difficult imaging them. The length and width of the structure were determined from the TEM to be ~36 and ~25 nm. The length and width were caDNAo designed to be ~38 and

24 nm, respectively. The slight deviations could be attributed to the preparations on the TEM grid.

The use of biotin-streptavidin as a linking method has a long history. Biotin is a water soluble B-vitamin and is present in all living things in minute amounts. Biotin is a very small molecule and when used in biotinylation, does not usually alter many properties of the structures (Diamandis and Christopoulos, 1991). Streptavidin is a 52 kDa protein found in *Streptomyces avidinii*. Streptavidin is a symmetric tetramer which forms a brick with dimensions of 6 × 5 × 4 nm and a pair of biotin binding sites per each of the two 6 × 4 nm faces (Ringler and Schulz, 2003). It does have four high affinity binding sites for biotin and the binding of biotin to streptavidin is one of the strongest non-covalent interactions known



**Figure 3.** caDNAno interface of a section of the Path panel showing two designed connection sites (shown with violet and yellow colors).


in nature. The high affinity constant of interaction of biotin with streptavidin is about 10 times greater than the interaction of ligands with specific antibodies which ensures that the complex is stable even in harsh conditions of pH changes and multiple washings. The binding of biotin to streptavidin is very specific such that the binding is directed only to the target. One of the participating components in the biotin-streptavidin system should always be biotinylated (Diamandis and Christopoulos, 1991). Many scientists have utilized this biotin-streptavidin high affinity interaction to direct several processes and applications (Chiruvolu et al., 1994; Eskelinen et al., 2011; Lyonnais et al., 2008; Qi et al., 2005; Ringler and Schulz, 2003). Many of the research associating DNA origami with the biotin-streptavidin interaction has focused on decorating the origami template with other functional materials (Eskelinen et al., 2011; Lyonnais et al., 2008).

In order to connect the DNA origami cross-like structures using biotin-streptavidin interaction, we designed the sites where the connections were to be made. These connection sites were designed at the two extreme ends of the long axis of each of the cross-like structure. We designed two DNA single strands at each connection site. These two single strands were biotinylated at the ends (3' ends) that extend outside the origami structure as shown in figure 3. The connection sites are shown in Figure 3 indicated with violet and yellow colors. The two designed DNA single strands at each of the connection sites were extended with an 8 base sequence ATGCATGC for sufficient flexibility to the DNA strands so that the structure will not be strained. This is significant since it makes it easier for biotinylated strands from two structures to have easy access to the binding streptavidin. To connect the cross-like structure

to another cross-like structure at the two positions indicated with violet and yellow colors in figure 3, all the generated sequences from caDNAno were used in addition to the sequences from the two designed connection sites that are extended with biotin.

Figure 4 shows the connecting process of three DNA origami cross-like structures using biotin-streptavidin interaction. After annealing and purification of the folded cross-like structures, we added a 20  $\mu$ M 20  $\mu$ l solution of streptavidin to a purified 20  $\mu$ l solution of the origami cross-like structures and the mixture was incubated overnight at 4°C. After incubation, unbound streptavidin was removed using spin column filtration. The resulting solution was again washed with EDTA. After washing, the solution was mixed with purified 20  $\mu$ l of the origami solution and the mixture incubated for two days at 4°C. Since streptavidin has four binding sites to biotin, one streptavidin molecule will bind two cross-like structures together. When streptavidin was added to the annealed DNA origami solution, two of its binding sites bonded with the two biotin molecules attached to the DNA origami template at one side. The same process also happens at the opposite side of the DNA origami template. In all the situations, two binding sites on the streptavidin are left free to bind to the biotin attached to the new DNA origami structure. We characterized the structures with TEM.

Figure 5 shows the TEM images of the connected structures at three different resolutions. We see in the images (Figure 5a to 5c) that the structures are only connected at the sites (ends of the long axis) where we have biotinylation. This shows that the connection came about through the biotin-streptavidin interaction and not base stacking interactions since we removed all the end sequences that are responsible for base stacking interactions. Since we biotinylated both lateral ends of the



**Figure 4.** Design schematic of connecting three DNA origami cross-like structures together using the biotin-streptavidin interaction. As a first step, DNA origami cross-like structures (folding of scaffold by staple strands) biotinylated on two opposite sides with four different DNA strands are mixed with streptavidin to form the origami-streptavidin complex. The origami-streptavidin complex is purified to remove excess streptavidin and mixed with biotinylated origami structures to form the connected origami structures.

cross-like structure, it is possible for the connections to continue until both biotinylated strands and attached streptavidins are used up (Figures 5). Figure 5a shows only two DNA origami cross-like structures connected with a total length of approximately 69 nm. Figures 5b and 5c show the connection of five and four origami structures, respectively. The approximate lengths determined from the TEM images are respectively 207 nm for the five cross-like structures in Figure 5b and 145.5 nm for the four structures in Figure 5c. These lengths compare favorably with the length determined from caDNAo which has already been stated. We also observed that longer chains were not formed as we had assumed from the design. This could be that the streptavidin used was not enough. The fact that longer chains were not formed may also be due to the incubation period which might be short.

## Conclusion

DNA origami structures can bind end-to-end through sticky end interactions. These interactions are always undesirable and efforts are made to remove them. Even if these interactions are needed, they are not strong


enough. We have demonstrated the use of the biotin-streptavidin interaction to connect DNA origami structures even though longer chains were not realized. This interaction is very strong and could be used to form DNA origami networks. Assembly of two different configurations has been shown. These configurations consist, respectively, of two, four, and different cross-like origami structures which are connected together end-to-end. It was difficult quantifying the overall yields of our structures, but it was easy to find many structures on the TEM grids sufficient for our characterization analyses.

## Conflict of interests

The authors did not declare any conflict of interest.

## ACKNOWLEDGEMENTS

This work was supported by the National Basic Research Program of China (973 Program, Grant 2011CB013004) and Major Project of State Key Laboratory of Tribology, Tsinghua University (SKLT10A02).



**Figure 5.** TEM images of the connected origami structures at two opposing connecting sites. Different scales (a) 100 nm, (b) 50 nm, and (c) 20 nm showing the lateral connections of the structures.

## REFERENCES

- Amoako G, Ye R, Zhuang L, Yang X, Shen Z, Zhou M (2013). DNA origami site-specific arrangement of gold nanoparticles. *Nano* 8: 13500641-135006411.
- Castro CE, Kilchherr F, Kim D-N, Shiao EL, Wauer T, Wortmann P, Bathe M, Dietz H (2011). A primer to scaffolded DNA origami. *Nat. Methods* 8:221-229.
- Chen JH, Seeman NC (1991). Synthesis from DNA of a molecule with the connectivity of a cube. *Nature* 350: 631-633.
- Chiruvolu S, Walker S, Israelachvili J, Schmitt F-J, Leckband D, Zasadzinski JA (1994). Higher order self-assembly of vesicles by site-specific binding. *Science* 264:1753-1756.
- Diamandis EP, Christopoulos TK (1991). The biotin-(strept) avidin system: Principles and applications in biotechnology. *Clin. Chem.* 37:625-636.
- Ding B, Deng Z, Yan H, Cabrini S, Zuckermann RN, Bokor J (2010). Gold nanoparticle self-similar chain structure organized by DNA Origami. *J. Am. Chem. Soc.* 132:3248-3249.
- Douglas SM, Dietz H, Liedl T, Hogberg B, Graf F, Shih WM (2009b). Self-Assembly of DNA into nanoscale three-dimensional shapes. *Nature* 459:414-418.
- Douglas SM, Marblestone AH, Teerapittayanon S, Vazquez A, Church GM, Shih WM (2009a). Rapid prototyping of 3D DNA-origami shapes with caDNAo. *Nucleic Acids Res.* 37:5001-5006.
- Ekani-Nkodo A, Kumar A, Fygenon DK (2004). Joining and Scission in the Self-Assembly of Nanotubes from DNATiles. *Phys. Rev. Lett.* 93:268301-268304.
- Eskelinen A-P, Kuzyk A, Kaltiaisenaho TK, Timmermans MY, Nasibulin AG, Kauppinen EI, Törmä P (2011). Assembly of Single-Walled Carbon Nanotubes on DNA-Origami Templates through Streptavidin-biotin interaction. *Small* 7:746-750.
- Fu TJ, Seeman NC (1993). DNA double-crossover molecules. *Biochemistry* 32:3211-3220.
- Hou S, Wang J, Martin CR (2005). Template-Synthesized DNA Nanotubes. *J. Am. Chem. Soc.* 127: 8586-8587.
- Jungmann R, Scheible M, Kuzyk A, Pardatscher G, Castro CE, Simmel FC (2011). DNA origami-based nanoribbons: assembly, length distribution, and twist. *Nanotechnology* 22:275301.
- Ke Y, Douglas SM, Liu M, Sharma J, Cheng A, Leung A, Liu Y, Shih WM, Yan H (2009). Multilayer DNA Origami Packed on a Square Lattice. *J. Am. Chem. Soc.* 131:15903-15908.
- Kuzuya A, Sakai Y, Yamazaki T, Xu Y, Komiyama M (2011). Nanomechanical DNA origami 'single-molecule beacons' directly imaged by atomic force microscopy. *Nat. Commun.* 2:449-456.
- Lavella GJ, Jadhav AD, Maharbiz MM (2012). A Synthetic Chemomechanical Machine Driven by Ligand-Receptor Bonding. *Nano Lett.* 12:4983-4987.
- Li H, Park SH, Reif JH, LaBean TH, Yan H (2004). DNA templated self-assembly of protein and nanoparticle linear arrays. *J. Am. Chem. Soc.* 126: 418-419.
- Li XJ, Yang XP, Qi J, Seeman NC (1996). Antiparallel DNA double crossover molecules as components for nanoconstruction. *J. Am. Chem. Soc.* 118: 6131-6140.
- Liu F, Sha R, Seeman NC (1999). Modifying the surface features of two-dimensional DNA crystals. *J. Am. Chem. Soc.* 121:917-922.
- Lyonnais S, Goux-Capes L, Christophe Escude, Cote D, Filoramo A, Bourgoin J-P (2008). DNA-carbon nanotube conjugates prepared

- by a Versatile Method Using Streptavidin–Biotin Recognition. *Small* 4:442-446.
- Maune HT, Si-ping H, Barish RD, Bockrath M, Goddard III WA, Rothmund PWK, Winfree E (2010). Self-assembly of carbon nanotubes into two-dimensional geometries using DNA origami templates. *Nat. Nano* 5(1):61-66.
- Pilo-Pais M, Goldberg S, Samano E, LaBean TH, Finkelstein G (2011). Connecting the Nanodots: Programmable Nanofabrication of Fused Metal Shapes on DNA Templates. *Nano Lett.* 11:3489–3492.
- Qi K, Zhou C, Walker AV, Wooley KL, Jhaveri SB, Sogah DY, Malkoch M, Beinhoff M, Carter KR, Hawker CJ (2005). Biotin/streptavidin recognition on polymer brushes and self-assembled monolayers. *Polymer Prepr.* 46:363.
- Ringler P, Schulz GE (2003). Self-Assembly of Proteins into Designed Networks. *Science* 302:106-109.
- Rothmund P (2006). Folding DNA to create nanoscale shapes and patterns. *Nature* 440:297-302.
- Seeman NC (1982). Nucleic acid junctions and lattices. *J. Theor. Biol.* 99:237–247.
- Seeman NC (2003). DNA in a material world. *Nature* 421:427–431.
- Shen X, Song C, Wang J, Shi D, Wang Z, Liu N, Ding B (2012). Rolling up gold nanoparticle-dressed DNA origami into three-dimensional plasmonic Chiral nanostructures. *J. Am. Chem. Soc.* 134: 146-149.
- Winfree E, Liu F, Wenzler LA, Seeman NC (1998). Design and self-assembly of two-dimensional DNA crystals. *Nature* 394:539-544.

Full Length Research Paper

## Reproductive performance of dairy cows affected by endometritis, pododermatitis and mastitis

Thaïsa Campos Marques<sup>1</sup>, Karen Martins Leão<sup>2\*</sup>, Moraima Castro Rodrigues<sup>2</sup>,  
Natalia do Carmo Silva<sup>1</sup> and Rossane Pereira da Silva<sup>2</sup>

<sup>1</sup>Programa de Pós-graduação em Zootecnia, Universidade Federal de Goiás (UFG), Rod. Goiânia-Nova Veneza, Caixa Postal 131, 74690-900, Goiânia, GO, Brasil.

<sup>2</sup>Programa de Pós-graduação em Zootecnia, Instituto Federal de Educação, Ciência e Tecnologia Goiano (IF GOIANO), Rod. Sul Goiana Km 01, Zona Rural, Rio Verde - GO - Brasil, 75.901-970, Caixa Postal 66, Rio Verde, GO, Brasil.

Received 25 March, 2015; Accepted 3 July, 2015

The effects of endometritis, pododermatitis and clinical mastitis on the conception rate and calving-conception interval of multiparous and primiparous cows after fixed-time artificial insemination (FTAI) were evaluated. Clinical endometritis was diagnosed by ultrasonography 20-40 days postpartum upon observation of fluid in the uterine lumen. Cows with clinical endometritis were treated intramuscularly with 2 mg/kg ceftiofur hydrochloride over three consecutive days. Forty-five days after delivery, multiparous and primiparous cows with normal uteri according to ultrasonography were selected for the study, fixed and inseminated by FTAI. To identify animals with hoof problems and clinical mastitis and to define their respective groups, the cows were observed daily during morning and nightly milking for up to 60 days after FTAI, and animals with hoof lesions were treated. Animals with clinical mastitis were treated with intramammary infusion containing 88 mg cefquinome sulphate every 12 h after milking for four days. The conception rate of multiparous cows with clinical endometritis at 30 and 60 days after FTAI was negatively affected compared with that of healthy cows with pododermatitis. However, clinical endometritis did not influence the primiparous category, whereas pododermatitis and clinical mastitis did not influence the conception rate of any category at 30 and 60 days after FTAI. Differences were not observed between primiparous or multiparous cows in the calving-conception interval.

**Key words:** Lactation, pregnancy, health, fertility.

### INTRODUCTION

The postpartum period is critical for the remainder of a cow's reproductive life (Dohmen et al., 2000). Uterine infections correspond to an increase in the calving

interval; discard rate and services required per conception and to a reduction in production (Leblanc et al., 2002; Sheldon et al., 2008). Infections of cattle limbs

\*Corresponding author. E-mail: karenleao2@yahoo.com.br. Tel: +55-64-3620-5637, Fax: +55-64-3620-5640.

cause stress and reduce fertility and pregnancy rates (Sheldon, 1997). Cows with lameness have a higher number of services per conception, longer period of service and increased incidence of metritis and mastitis than healthy cows (Souza et al., 2006). Another disease that can influence the reproductive performance of cows is mastitis, which is a major concern in dairy cattle production (Carneiro et al., 2004). The mechanisms by which mastitis interferes with embryonic survival and mortality are not fully understood, but studies have shown that there may be a relationship between mastitis and reduced pregnancy rates (Hansen et al., 2004).

This study therefore aimed at evaluating the effects of clinical endometritis, pododermatitis and clinical mastitis on the conception rate and calving-conception interval of primiparous and multiparous lactating dairy cows after fixed-time artificial insemination (FTAI).

## MATERIALS AND METHODS

The experiment was conducted on a dairy farm located in the municipality of Montividiu, southwest Goiás State, Brazil (latitude 17°20'5.7" and longitude 51°18'46.7"). During the experiment, lactating Holstein cows were confined in wooded feedlots supplied with drinking troughs. The cows received a complete diet consisting of quality corn silage and a balanced concentrate for milk production, which was distributed four times with the aid of a mixing wagon. The effects of endometritis, pododermatitis and clinical mastitis on the conception rate and calving-conception interval of multiparous and primiparous cows after FTAI were evaluated from May to August, 2013. The experimental animals ( $n = 356$ ) were divided into two categories: multiparous cows, with an average milk production of  $26.7 \pm 3.6$  kg milk/day, and primiparous cows, with an average milk production of  $20.4 \pm 2.8$  Kg milk/day. Between 20 and 40 days after birth, the animals were reproductively evaluated by ultrasonography. Cows with clinical endometritis determined by observations of fluid in the uterine lumen were treated with 2 mg/kg ceftiofur hydrochloride (CEF50<sup>®</sup>, Agenor União Saúde Animal, Embu-Guaçu, SP, Brasil) intramuscularly for three consecutive days.

Animals with uteri without signs of infection upon clinical examination and ultrasonography (Mindray<sup>®</sup> DP3300 VET) were selected for the study after the voluntary waiting period of 50 days. The age of the experimental animals was  $62.3 \pm 7.4$  days on average after birth, and they had a body condition score between 2.5 and 3.5 on a scale from 1 to 5, with 1 indicating very thin and 5 indicating very fat (Ferguson et al., 1994). The cows were synchronised and inseminated at a fixed time according to the following protocol: on the first day (D0), the cows received an intravaginal progesterone implant (Cronipres<sup>®</sup>, Biogénesis-Bagó, Garin, Buenos Aires, Argentina) and intramuscular application of 2 mg oestradiol benzoate (Bioestrogen<sup>®</sup>, Biogénesis-Bagó) After eight days (D8), the implant was removed, and 0.15 mg sodium cloprostenol (Croniben<sup>®</sup>, Biogénesis-Bagó), 300 UI equine chorionic gonadotropin (Folligon<sup>®</sup>, Intervet International B.V., Boxmeer, Holland) and 1 mg oestradiol cypionate (ECP<sup>®</sup>, Pfizer, Pharmacia and Upjohn Company, NY, USA) were administered. Forty-eight hours after implant removal (D10), 0.004 mg buserelin acetate Cows were observed daily during morning and afternoon milking for up to 60 days after FTAI to identify animals with hoof problems and clinical mastitis. Animals with hoof lesions were restrained in a hoof trimming chute for cleaning and corrective treatment. Animals with clinical mastitis were medicated with an intramammary infusion

containing 88 mg cefquinome sulphate (Cobactan VL<sup>®</sup>, Intervet International B.V.) after milking and every 12 h for four days. (Sincroforte<sup>®</sup>, Ouro Fino, Cravinhos, SP, Brasil) was administered intramuscularly, and the artificial insemination was performed.

Thus, the groups were divided into healthy cows ( $n = 106$ ), cows treated for clinical endometritis ( $n = 83$ ), cows affected by pododermatitis ( $n = 97$ ) and cows suffering from clinical mastitis ( $n = 70$ ), within each category of multiparous and primiparous. Pregnancy was diagnosed at 30 and 60 days after FTAI through ultrasonography with a 5.0 MHz linear transducer (DP 3300, Mindray, Nanshan, Shenzhen, China).

Data were statistically analysed using R software (R Core Team, 2014). Comparisons of the conception rate were performed by the nonparametric chi-square test, whereas the average calving-conception interval was analysed by Tukey's test, both with a 5% significance level.

## RESULTS

The conception rate at 30 days after FTAI of multiparous cows affected by and treated for clinical endometritis (18.8%) was significantly lower than the conception rate of healthy cows (41.6%,  $P = 0.0262$ ) and cows affected by pododermatitis (41.7%,  $P = 0.0170$ ). However, multiparous cows affected by and treated for clinical endometritis had the same reproductive performance as cows affected by clinical mastitis (35.3%). For primiparous cows, neither of the evaluated diseases affected the conception rate at 30 days after FTAI compared with healthy cows (Table 1). For the diseases evaluated in this study, only clinical endometritis (15.6%) affected the conception rate at 60 days after the FTAI of multiparous cows compared with that of healthy cows (37.3%,  $P = 0.0389$ ). Differences were not observed between the other groups of multiparous cows or primiparous cows (Table 2). Table 3 shows that in both categories of cows (multiparous and primiparous); differences were not observed in the calving-conception interval of healthy cows and cows affected by the diseases evaluated here.

## DISCUSSION

In the multiparous category, the conception rate at 30 and 60 days after the FTAI of cows affected by endometritis was significantly lower than the conception rate of healthy cows. These results are consistent with a study conducted nearly three decades ago in which more cows with normal puerperium became pregnant in the first service (42%) compared with cows with some postpartum abnormality (24%) (Benmrad and Stevenson, 1986). Similar results were not observed in the primiparous cows of the study. Studies have found that the presence of endometritis has no effect on fertility when considering the conception rate at first insemination (Kasimanickam et al., 2006). The same authors explained that the use of hormonal protocols for FTAI, such as ovsynch or presynch, promotes uterine immune



**Table 1.** Conception rates at 30 days after the fixed-time artificial insemination of multiparous and primiparous health dairy cows, cows treated for clinical endometritis, cows affected by pododermatitis and cows suffering from clinical mastitis.

Category	Conception rate n (%)			
	Healthy	Endometritis	Pododermatitis	Mastitis
Multiparous (n = 205)	41.6 <sup>a</sup> (26/62)	18.8 <sup>b</sup> (9/47)	41.7 <sup>a</sup> (24/58)	35.3 <sup>ab</sup> (13/38)
Primiparous (n = 151)	43.8 <sup>a</sup> (19/44)	28.6 <sup>a</sup> (10/36)	33.3 <sup>a</sup> (13/39)	22.2 <sup>a</sup> (7/32)

Values followed by different letters in the same row are significantly different ( $P < 0.05$ ).

**Table 2.** Conception rate at 60 days after the fixed-time artificial insemination of multiparous and primiparous health dairy cows, cows treated for clinical endometritis, cows affected by pododermatitis and cows suffering from clinical mastitis.

Category	Conception rate n (%)			
	Healthy	Endometritis	Pododermatitis	Mastitis
Multiparous (n = 205)	37.3 <sup>a</sup> (23/62)	15.6 <sup>b</sup> (7/47)	33.3 <sup>ab</sup> (19/58)	29.4 <sup>ab</sup> (11/38)
Primiparous (n = 151)	41.3 <sup>a</sup> (18/44)	28.6 <sup>a</sup> (10/36)	33.3 <sup>a</sup> (13/39)	22.2 <sup>a</sup> (13/39)

Values followed by different letters in the same row are significantly different ( $P < 0.05$ ).

**Table 3.** Mean ( $\pm$  SD) of the calving-conception interval (in days) of multiparous and primiparous healthy dairy cows, cows treated for clinical endometritis, cows affected by pododermatitis and cows suffering from clinical mastitis.

Category	Average calving-conception interval $\pm$ Standard Deviation (days)			
	Healthy	Endometritis	Pododermatitis	Mastitis
Multiparous	149.94 $\pm$ 68.46 a	169.37 $\pm$ 96.02 a	188.80 $\pm$ 104.11 a	174.13 $\pm$ 116.46 a
Primiparous	156.69 $\pm$ 68.61 a	162.33 $\pm$ 111.79 a	181.00 $\pm$ 80.01 a	175.62 $\pm$ 86.42 a

Averages followed by the same letter on the same row do not differ from each other ( $P < 0.05$ ).

mechanisms, thereby minimising the effects of endometritis. However, several studies have shown that uterine infections caused economic losses to livestock because they increase the number of services and reduce production (Andrade et al., 2005).

Uterine discharge does not affect the number of services per conception, although the calving interval and first insemination is longer in animals with endometritis (Williams et al., 2005). Differences in the calving-conception interval between healthy cows and cows treated for endometritis in multiparous (149.94  $\pm$  68.46 versus 169.37  $\pm$  96.02) and primiparous (156.69  $\pm$  68.61 versus 162.33  $\pm$  111.79) cows were not observed in this study. These results are consistent with the results of another study in which the calving-conception interval did not change in cows that had endometritis, were treated by intra-uterine infusions of ceftiofur and received PGF2 $\alpha$  in the oestrus synchronisation protocol ( $P > 0.05$ ) (Galvão et al., 2009).

Recent studies have shown that cows treated for endometritis experienced an average delay of 28 days in the calving-conception interval, and this delay can cause greater economic losses than what is experienced during disease treatment because a reduction in the conception rate and increase in the calving-conception interval cause a longer calving interval and lower milk production (Marques et al., 2012). These data are consistent with another study that reported a longer calving-conception interval for cows treated for endometritis compared with healthy cows (151 versus 119 days) (Leblanc et al., 2002).

Compared with the results obtained in this study, Melendez et al. (2003) showed that lame cows had lower conception rates than the control group at first service (17.5% versus 42.6%). Studies have shown that hoof problems reduced the ovarian activity of Holstein cows at 60 days postpartum (Gabarino et al., 2004), which is important because cows must experience ovarian cycling

to expel contaminants from the uterus (Benmrad and Stevenson, 1986). Another study observed conception rates at first service of 56 and 46% in cows without hoof problems and cows with lameness, respectively (Collick et al., 1989). These rates are greater than the values observed in this study, and this difference can be explained by the fact that oestrus synchronisation was performed in Collick et al. (1989) and FTAI was performed in the study.

In this study, the calving-conception interval was not affected by hoof lesions in the multiparous ( $149.94 \pm 68.46$  versus  $188.80 \pm 104.11$ ) and primiparous ( $156.69 \pm 68.61$  versus  $181.00 \pm 80.01$ ) cows. However, the multiparous cows with pododermatitis tended ( $P = 0.0937$ ) to have a longer calving-conception interval, which was 38.86 days greater than that of the healthy cows. When the hoof lesions affected the hindlimbs and forelimbs, the calving interval at first service increased by 2.9 and 4.6 days, respectively (Barkema et al., 1994). Other authors have reported that lame cows showed longer service periods than healthy cows (266 versus 200.5 days, respectively) and an increased incidence of metritis (25% versus 12.5%) and mastitis (60% versus 29%) compared with normal cows (Souza et al., 2006). Lame cows feel pain and stress that may predispose them to certain diseases, such as metritis and mastitis, and increased glucocorticoids, which cause premature luteolysis (Melendez et al., 2003).

In this study, the primiparous cows affected by mastitis (22.2%) tended to have a lower conception rate than healthy cows (43.8%) at 30 days ( $P = 0.0608$ ). However, the embryonic and foetal mortality between 30 and 60 days was low for multiparous cows and absent in primiparous cows suffering from mastitis. A reduced conception rate in animals with mastitis may be related to the mechanism of maternal recognition because mastitis promotes the production of several bioactive molecules that can disrupt the functioning of the reproductive system (Slebodzinski et al., 2002).

According to the literature, prostaglandins are under the control of a several cytokines, including tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin (IL)-1 $\alpha$ , which can increase the secretion of prostaglandin F2 $\alpha$  (PGF2 $\alpha$ ) by the endometrium (Skarzynski et al., 2000). It has been shown that there is an increase of mRNA for IL-1 $\alpha$ , IL-1 $\beta$ , TNF- $\alpha$ , IL-10 and IL-12 and protein for TNF- $\alpha$  in cells derived from milk that cause an infection of mammary glands. Thus, the release of cytokines into blood during mastitis can induce the release of PGF2 $\alpha$  and premature luteolysis (Waller et al., 2003).

Premature luteolysis was observed in cows suffering from mastitis, although it was not observed in normal cows. Furthermore, the oestrus cycle was longer when mastitis occurred during the follicular phase, and these results indicate that mastitis can affect postpartum ovarian activity in dairy cows (Huszenicza et al., 2005). Differences were not observed in the calving-conception interval of cows that were healthy and affected by mastitis

in both the multiparous ( $149.94 \pm 68.46$  versus  $174.13 \pm 116.46$ , respectively) and primiparous categories ( $156.69 \pm 68.61$  versus  $175.62 \pm 86.42$ , respectively).

Although significant differences were not observed in the calving-conception interval of the categories evaluated in the study, dairy farmers can suffer economic losses because of disease treatment and lower milk production. Therefore, adequate nutritional, sanitary and reproductive management can help reduce unnecessary expenses that can be converted into revenue.

## Conclusion

Based on the results obtained in this study, endometritis was shown to affect the conception rate of multiparous cows at 30 and 60 days after FTAI, although it does not influence the primiparous cows. Pododermatitis and clinical mastitis do not affect the conception rate of either the multiparous or primiparous cows at 30 and 60 days after FTAI.

## Conflict of interests

The author(s) did not declare any conflict of interest.

## ACKNOWLEDGEMENTS

The authors are grateful to the owners and staff at Fazenda Gamela, who spared no effort in performing these experiments, and appreciate the IF-Goiano - Rio Verde Campus for their support in implementing this study.

## Ethics committee

The study was approved by the Ethics Committee of the Goias Federal Institute of Education, Science and Technology (Instituto Federal de Educação, Ciência e Tecnologia Goiano – IF Goiano) and filed under protocol number 033/2012.

## REFERENCES

- Andrade JRA, Silva N, Silveira W, Teixeira MCC (2005). Estudo epidemiológico de problemas reprodutivos em rebanhos bovinos na bacia leiteira de Goiânia [An epidemiological study of reproductive failure in dairy herds from Goiânia]. *Arq. Bras. Med. Vet. Zootec.* 57(06):720-725.
- Barkema HW, Westrik JD, Keulen KAS, Schukken YH, Brand A (1994). The effects of lameness on reproductive performance, milk production and culling in Dutch dairy farms. *Prev. Vet. Med.* 20:249-259.
- Benmrad MF, Stevenson SJ (1986). Gonadotropin-releasing hormone and prostaglandin F2 $\alpha$  for postpartum dairy cows: oestrous, ovulation, and fertility traits. *J. Dairy Sci.* 69:800-811.
- Carneiro DMVF, Domingues PF, Vaz AK (2009). Imunidade inata da

- glândula mamária bovina: resposta a infecção. *Cienc. Rural* 39(6):1934-1943.
- Collick DW, Ward WR, Dobson H (1989). Associations between types of lameness and fertility. *Vet. Rec.* 125:103-106.
- Dohmen MJW, Joop K, Sturk A, Bols PEJ, Lohuis JACM (2000). Relationship between intra-uterine bacterial contamination, endotoxin levels and the development of endometritis in postpartum cows with dystocia or retained placenta. *Theriogenology* 54(7):1019-1032.
- Ferguson JD, Galligan DT, Thomsen N (1994). Principal Descriptors of Body Condition Score in Holstein Cows. *J. Dairy Sci.* 77(9):2695-2703.
- Gabarino EJ, Hernandez JA, Shearer JK, Risco CA, Thatcher WW (2004). Effect of lameness on ovarian activity in postpartum Holstein cows. *J. Dairy Sci.* 87(12):4123-4131.
- Galvão KN, Greco LF, Vilela JM, Sá Filho MF, Santos JE (2009). Effect of intrauterine infusion of ceftiofur on uterine health and fertility in dairy cows. *J. Dairy Sci.* 92(4):1532-1542.
- Hansen PJ, Soto P, Natzke RP (2004). Mastitis and Fertility in Cattle – Possible Involvement of Inflammation or Immune Activation in Embryonic Mortality. *Am. J. Reprod. Immunol.* 51(4):294-301.
- Huszenicza G, Janosi S, Kulcsa M, Korodi P, Reiczigel J, Katai L, Peters AR, De Rensis F (2005). Effects of clinical mastitis on ovarian function in post-partum dairy cows. *Reprod. Domest. Anim.* 40(3):199-204.
- Kasimanickam R, Cornwell JM, Nebel RL (2006). Effect of presence of clinical and subclinical endometritis at the initiation of presynch-ovsynch program on the first service pregnancy in dairy cows. *Anim. Rep. Sci.* 95(3):214-223.
- Leblanc SJ, Duffield TF, Leslie KE, Bateman KG, Keefe GP, Walton JS, Johnson WH (2002). Defining and diagnosing postpartum clinical endometritis and its impact on reproductive performance in dairy cows. *J. Dairy Sci.* 85(9):2223-2236.
- Marques TC, Rodrigues MC, Silva NC, Oliveira MC, Leão KM, Viu MAO (2012). Desempenho reprodutivo de vacas leiteiras acometidas e tratadas de endometrite clínica. In: Resumos da 49ª Reunião Anual da Sociedade Brasileira de Zootecnia (Brasília, Brasil). Available at: <[http://eventweb.com.br/sbz2012/home-event/schedule.php?sessao=&q=endometrite&area=177&busca\\_por=tudo](http://eventweb.com.br/sbz2012/home-event/schedule.php?sessao=&q=endometrite&area=177&busca_por=tudo)>. Access: 11/2014.
- Melendez P, Bartolomeu J, Archbald LF, Donovan A (2003). The association between lameness, ovarian cysts and fertility in lactating dairy cows. *Theriogenology* 59(3):927-937.
- R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>.
- Sheldon IM, Williams EJ, Miller ANA, Nash DM, Herath S (2008). Uterine diseases in cattle after parturition. *Vet. J.* 176(1):115-121.
- Sheldon M (1997). Bovine fertility-practical implications of the maternal recognition of pregnancy. *Farm Anim. Pract.* 19(10):546-54.
- Skarzynski DJ, Miyamoto Y, Okuda K (2000). Production of prostaglandin F2a by cultured bovine endometrial cells in response to tumour necrosis factor a: cell type specificity and intracellular mechanisms. *Biol. Reprod.* 62:1116-1120.
- Slebodzinski AB, Malinowski E, Lipczak W (2002). Concentrations of triiodothyronine (T3), tumour necrosis factor-a (TNF-a) and interleukin-6 (IL-6) in milk from healthy and naturally infected quarters of cows. *Res. Vet. Sci.* 72(1):17-21.
- Souza RC, Ferreira PM, Molina LR, Carvalho AU, Facury Filho EJ (2006). Perdas econômicas ocasionadas pelas enfermidades podais em vacas leiteiras confinadas em sistema free stall. *Arq. Bras. Med. Vet. Zootec.* 58(6):982-987.
- Waller KP, Colditz IG, Ostensson K (2003). Cytokines in mammary lymph and milk during endotoxin-induced bovine mastitis. *Res. Vet. Sci.* 74(1):31-36.
- Williams EJ, Fischer DP, Pfeiffer DU, England GCW, Noakes DE, Dobson H, Sheldon IM (2005). Clinical evaluation of postpartum vaginal mucus reflects uterine bacterial infection and the immune response in cattle. *Theriogenology* 63(1):102-117.



# African Journal of Biotechnology

## Related Journals Published by Academic Journals

- *Biotechnology and Molecular Biology Reviews*
- *African Journal of Microbiology Research*
- *African Journal of Biochemistry Research*
- *African Journal of Environmental Science and Technology*
- *African Journal of Food Science*
- *African Journal of Plant Science*
- *Journal of Bioinformatics and Sequence Analysis*
- *International Journal of Biodiversity and Conservation*

**academic**Journals